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CHAPTER 1: GENERAL INTRODUCTION 
INTRODUCTION PART I: HEXOKINASE I INTERACTIONS WITH VDAC 
The mitochondrial voltage dependent anion selective channel (VDAC) was first identified 
in 1976. The family of VDAC proteins includes three isoforms, VDAC1, VDAC2, and VDAC3, 
all are located on the outer mitochondrial membrane (OMM). The most abundant isoform on the 
OMM is VDAC1, which is in fact, the most abundant of all embedded mitochondrial membrane 
proteins. It is well established that VDAC regulates the energy balance of mitochondria and the 
entire cell by facilitating the exchange of metabolites between mitochondria and cytoplasm (1-6). 
The monomer form of VDAC has a pore diameter of 36 Å, as measured from models of X-ray 
and NMR structures (54, 55) (Fig. 1).  Most metabolites are small enough to pass through this 
pore; however, proteins in their folded conformation are too large to cross the membrane by way 
of the pore. The interior of pore has many positively charged residues that may be the basis for 
the anion selectivity, but VDAC also regulates levels of cytosolic and mitochondrial metabolites 
of respiration and ions, especially that of Ca2+ (7-9). 
 
FIGURE 1. VDAC1 structure (PDB 3EMN). A and B indicate side and top views, respectively, 
of the19-stranded β-barrel (green). The N-terminal helix is magenta and Glu73 is blue. 
 
VDAC is not surprisingly one of the key players in cell survival. Silencing the expression 
of VDAC1 inhibited cell growth through a reduction in energy production (10). Endogenous 
VDAC1 expression in transformed primary embryonal human kidney T-Rex-293 cells was 
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suppressed by 70-90% by shRNA techniques. The decrease in VDAC levels dramatically 
reduced cell growth, reduced ATP synthesis by five-fold and decreased cellular levels of ATP 
and ADP by 50% (10). 
VDAC also plays a role in apoptosis. Apoptosis (Programmed Cell Death) is a natural 
process triggered in cells that are functionally compromised. Apoptosis is an indispensable part 
of the development and function of an organism. There are at least two broad pathways known as 
"extrinsic" and "intrinsic". The extrinsic pathway begins outside a cell in response to the 
extracellular environment that requires cell death. The intrinsic apoptosis pathway begins when 
an injury (or dysfunction) occurs within the cell. Apoptosis involving the mitochondrion is the 
best known intrinsic pathway (11, 12), and there is substantial evidence suggesting VDAC is a 
critical player in the release of apoptogenic proteins from mammalian mitochondria (2, 5, 6, 14-
15). Release of cytochrome c, interactions between pro-apoptotic proteins and VDAC, and the 
triggering of cell death, are impacted by anti-VDAC antibodies, thus demonstrating the 
importance of VDAC in the intrinsic apoptosis pathway (16-18). Other evidence of VDAC 
involvement in apoptosis comes from over- and down-expression of VDAC levels in vivo. Over-
expression of human, murine, yeast, Paralichthys olivaceus, and rive VDAC induces apoptotic 
cell death regardless cell type (19-23). On the other hand, siRNA-mediated down-expression of 
VDAC prevented cell death induced by anti-apoptotic proteins (14). 
Another key player of the intrinsic apoptosis pathway relative to VDAC is hexokinase 
(HK). Four hexokinase isozymes are identified in mammalian tissue: I, II, III and IV (24, 25). 
Hexokinase I (HKI) (Fig. 2), is recognized as the “pacemaker of glycolysis” in brain tissue and 
the red blood cell (26). HKI is known to be highly expressed in kidneys, liver, intestines and 
lungs (27, 28). This enzyme binds the OMM in brain tissue (29). Mitochondrion-associated HKI 
may provide HKI with preferential access to newly formed mitochondrial ATP (29). HKI 
binding to the mitochondrion prevents the opening of the permeability transition pore (PTP) (30). 
The PTP presumably consists of VDAC of the outer mitochondrion membrane (31-36). HKI 
seems to interact with VDAC to close (or prevent) PTP opening (31, 32). Non-functional PTP 
causes loss of membrane potential, organelle swelling, cytosolic acidification, and the release of 
cytochrome c (30, 37). Released cytochrome c activates the caspase signaling pathway and 
initiates apoptosis (38-40). 
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FIGURE 2. Hexokinase type I structure (PDB 1DGK) with ADP (yellow) and glucose 
(magenta). C-half (green), N-half (cyan), and transition helix (red). 
 
Another line of evidence suggests that pro-apoptotic proteins (Bax, Bak, and Bim) trigger 
cytochrome c release without mitochondrial swelling (37, 41, 42). These pro-apoptotic proteins 
promote the assembly VDAC into the PTP (41, 42). Overexpression of VDAC causes apoptotic 
cell death (43, 44), however, over-expression of N-terminal truncated VDAC1 did not induce 
cells to release cytochrome c and the cells were resistant to apoptosis (13). The interaction 
between VDAC and HKI is governed by a specific residue in VDAC. The key residue Glu73 
prevents HKI from binding to mitochondria and prevents HKI-linked protection against 
apoptosis in cancer cells (43, 45). Moreover, chemical modification of Glu 73 eliminated the 
binding of HKI to mitochondria (23). Adding HKI to VDAC1 reconstituted in lipid membrane 
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reduced the channel conductance (30). HKI addition to mutant (Glu 73 to glutamine) mouse 
VDAC reconstituted in lipid membrane did not block channel conductance, inferring the failure 
of HKI to bind to mutant VDAC1 (45). HKI may antagonize the formation of apoptotic 
channels, thus some have gone so far as to label hexokinase as “guardian of the mitochondria” 
(46). Other proof of HKI association with VDAC comes from its co-localization with human 
VDAC-1, -2 and -3 (47), and its inhibition of ATP flux through VDAC1 (45). 
A number of small and physiological important ligands dissociate HKI from the 
mitochondrial outer membrane by binding to VDAC. Photoactive ATP analog, Bz-ATP 
(benzoyl-benzoyl-ATP), can bind to multiple sites on VDAC1 with low and high binding 
affinities (50). Mutating residues of the predicted nucleotide-binding site of VDAC1 reduced 
ATP cellular levels and cell growth (51). Other non-nucleotide ligands such as glucose 6-
phosphate cause release of HKI from the mitochondrial outer membrane by binding to the N-
terminal half of HKI (29). 
This dissertation establishes the attributes of ligands that bind to VDAC and cause the 
release of HKI.  The VDAC structure, determined by NMR and crystallographic methods, is a 
19-strand β-barrel with its N-terminal helix localized within the pore (54, 55). The function of 
VDAC is known from ion conductance through the OMM; however, existing structures have not 
provided a definitive mechanism for the voltage-dependent control of ion permeability.  We 
propose that nucleotide-induced release of HKI from mitochondria enables ion conductance, and 
that HKI and nucleotides compete for a common binding site on VDAC1 at the OMM. 
Fluorescent nucleotide analogs probe interactions of HKI with VDAC1. 
 
INTRODUCTION PART II: STRUCTURE AND STABILITY OF β-KETOACYL-ACYL-
CARRIER-PROTEIN (ACP) SYNTHASE III 
Escherichia coli employs a Type II system, typical of bacteria, plants and parasites in the 
phylum Apicomplexa, for the synthesis of fatty acids. In contrast, lower eukayotes and mammals 
employ a Type I system (56, 57). The two systems differ in the organization of enzymes 
underlying otherwise similar chemical reactions. Type I systems employ single multi-functional 
enzyme complexes to conduct the sequence of reactions that leads ultimately to the final fatty 
acids. In the Type II system, individual enzymes are responsible for each chemical step. Focus 
here is on the Type II system of E. coli, and specifically β-ketoacyl-acyl-carrier-protein (ACP) 
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synthase III (abbreviated KASIII or alternatively FabH after its gene). FabH initiates the 
biosynthesis of fatty acids. Although KASI (FabB) and KASII (FabF) can also initiate fatty acid 
biosynthesis in vitro, the principal in vivo pathway relies on initiation catalyzed by FabH (Fig. 3). 
The principle roles of FabB and FabF instead are in the elongation of fatty acids and in the 
termination of fatty acid biosynthesis. 
 
FIGURE 3. Schematic of fatty acid biosynthesis indicating roles for FabB, FabF, and FabH. 
 
FabH catalyzes a sequence of two reactions.  The first is the transfer of the acetyl group 
from acetyl-CoA to an active site cysteine (Cys112).  The second is the decarboxylation of 
malonyl-ACP with the concomitant transfer of the acetyl adduct from Cys112 to form 
acetoacetyl-ACP. Acetoacetyl-ACP undergoes reduction, dehydration and a second reduction 
(three chemical steps conducted by three enzymes) resulting in butyryl-ACP.  Transfer of the 
butyryl group from butyryl-ACP to the active site cysteine of FabB (KASI) or FabF (KASII) 
primes the elongation process (much like acetyl-CoA primes FabH).  Another molecule of 
malonyl-ACP (with concomitant decarboxylation) results in formation of butyryloacetate-ACP, 
followed by reduction, dehydration, and further reduction to give a six-carbon thioester of ACP 
(58). Subsequent cycles (condensation, reduction, dehydration and reduction) produces free 
palmitate as the final product. The importance of enzymes (FabB and FabF) in the termination of 
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chain elongation and in the accumulation of specific saturated and unsaturated fatty acids in the 
cell has been demonstrated (59). 
Most investigations of FabH focus on one of two areas: (i) enzyme inhibition as a means 
of limiting cell growth and (ii) enzyme engineering for the production of new fatty acids. 
Thiolectomycin, a known antibacterial agent, inhibits bacterial fatty acid synthases acting against 
FabB, FabF and FabH with IC50 values of 25, 6 and 110 μM, respectively (70). Cerulenin 
inhibits FabB, FabF and FabH with IC50 values of 3, 20 and >700 μM, respectively. Inhibition 
levels suggest similarities in the active sites of FabB and FabF that are not shared by FabH (56, 
61, 62). Moreover, if the goal is the development of an effective antimicrobial agent, then FabH 
is the best target due its role as the principal initiator of fatty acid biosynthesis in Type II systems 
(60, 63, 64). FabH selects acetyl-CoA over acyl-ACP, and in fact is distinguished from FabF and 
FabB by its preference for acetyl-CoA as a substrate. The engineering of biosynthetic pathways 
in E. coli to produce modified fatty acids and/or fatty acids of specific chain-length is a goal of a 
biorenewable economy. FabH discriminates against branching at the ω-terminus of the fatty acid 
(the reason for this is clear from structures presented in Chapter 5 of this thesis), but fatty acid 
synthase initiators from other organisms do accept larger and branched alkyl groups (n-propyl, 
isopropyl and t-butyl).  Hence, the possibility of engineering FabH to accept substrates in 
addition to acetyl-CoA may be possible. 
Crystallographic structures of FabH with few exceptions reveal a homodimer.  Previous 
work has revealed the presence of an acetyl adduct at Cys112 and the ordered binding of CoA at 
the active site that presumably closely resembles a productive complex of acetyl-CoA and the 
enzyme (65-68) (Fig. 4). These structural studies suggest specific functions for active-site 
residues in the Claisen condensation. Moreover, molecular dynamics simulations have been used 
to evaluate the stability of the FabH protein and models of the FabH-ACP complex. The 
simulations indicate that the substrate complex FabH adopts a more stable conformation than 
FabH itself (69). 
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FIGURE 4. FabH structure with acetylation of active site and CoA (PDB 1HNH). FabH (green), 
CoA (blue), and acetylated Cysteine residue 112 (stick). 
 
The major contribution of this thesis has been the recognition of the acetyl adduct form of 
FabH by halide anions. Work here verifies observations of an acetyl adduct, ordered binding of 
CoA to the active site and conformational disorder in the active site in the absence of ligands or 
adduct. The observation that FabH comes out of E. coli cells as the Cys112 adduct, suggest the 
primary in vivo state of the enzyme is the adduct intermediate, primed and ready to accept 
malonyl-ACP in the second step of the reaction mechanism. 
  
8 
 
DISSERTATION ORGANIZATION 
This dissertation is organized into six chapters. Chapter 1 covers the background 
literature, problems and objectives related to the research projects. Chapters 2, 3, 4, and 5 are 
papers prepared for publication in peer reviewed journals. Chapter 2 explores the mechanism of 
nucleotide release of HKI from OMM. Chapter 3 explores VDAC binding to nucleotides. 
Chapter 4 describes the determination and localization of binding of VDAC at an artificial 
vesicle. Work in Chapter 5 reveals mechanisms of halide and substrate stabilization of FabH.  
Conclusions and recommendations for future studies are in Chapter 6. 
 
REFERENCES 
 
1. Colombini M (2004) Mol. Cell. Biochem. 256-257, 107-115 
2. Lemasters J J; Holmuhamedov E (2006) Biochim. Biophys. Acta. 1762, 181-190 
3. Shoshan-Barmatz V; Gincel D (2003) Cell Biochem. Biophys. 39, 279-292 
4. Shoshan-Barmatz V; Israelson A (2005) J. Membr. Biol. 204, 57-66 
5. Tsujimoto Y; Shimizu S (2002) Biochemie. 84, 187-193 
6. Vyssokikh MY; Brdiczka D (2003) Acta. Biochim. Pol. 50, 389-404 
7. Gincel D; Zaid H; Shoshan-Barmatz V (2001) Biochem. J. 358, 147-155 
8. Deniaud A; Sharaf el dein O; Maillier E; Poncet D; Kroemer G; Lemaire C; Brenner C. (2007) 
Oncogene. 1-15  
9. Deniaud A; Rossi C; Berquand A; Homand J; Campagna S; Knoll W; Brenner C; Chopineau 
J. (2007) J. Am. Chem. Soc. 23, 3898-3905 
10. Abu-Hamad S; Sivan S, Shoshan-Barmatz V (2006) Proc Natl Acad Sci, 103:5787-5792 
11. Wilk S. (2005) Sci. STKE. 285, tr16 
12. Czerski L; Nunex G. (2004) J. Mol. Cell Cardiol. 37, 643-52 
13. Abu-Hamad S; Arbel N; Calo D; Arzoine L; Israelson A; Keinan N; Ben-Romano R; 
Friedman O; Shoshan-Barmatz V. (2009) J. Cell. Sci. 122, 1906-1916 
14. Tajeddine N; Galluzzi L; Kepp O; Hangen E; Morselli E; Senovilla L; Araujo N; Pinna G; 
Larochette N; Zamzami N; Modjtahedi N; Harel-Bellan A; Kroemer G. (2008) Oncogene, 27, 
4221-4231 
15. Yuan S; Fu Y; Wang X; Shi H; Huang Y; Song X; Li L; Song N; Luo Y. (2008) FASEB J. 
22, 2809-2820 
9 
 
16. Madesh M; Hajnoczky G. (2001) J. Cell. Biol. 155, 1003-1010 
17. Shimizu S; Matsuoka Y; Shinohara Y; Yoneda Y; Tsujimoto Y. (2001) J. Cell Biol. 152, 
237-250 
18. Zheng Y; Shi Y; Tian C; Jiang C; Jin H; Chen J; Almasan A; Tang H; Chen Q. (2004) 
Oncogene 23, 1239-1247 
19. Abu-Hamad S; Zaid H; Israelson A; Nahon E; Shoshan-Barmatz V. (2008) J Biol. Chem. 
283(19), 13482-13490 
20. Ghosh T; Pandey N; Maitra A; Brahmachari S K; Pillai B. (2007) PLoS. ONE 2, e1170 
21. Godbole A; Varghese J; Sarin A; Mathew M K. (2003) Biochim. Biophys. Acta. 1642, 87-96 
22. Lu A J; Dong C W; Du C S, Zhang Q Y. (2007) Fish. Shellfish. Immunol. 23, 601-613 
23. Zaid H; Abu-Hamad S; Israelson A; Nathan I; Shoshan-Barmatz V. (2005) Cell Death Differ. 
12, 751-760 
24. González, C; Ureta, T; Sánchez, R; Niemeyer, H. (1964) Biochem. Biophys. Res. Commun. 
16, 347-52.  
25. Katzen, H M; Schimke, R T. (1965) Proc. Natl. Acad. Sci. U S A.  54, 1218-25. 
26. Lowry, O H; Passonneau, J V. (1964) J. Biol. Chem. 239, 31-42.  
27. Katzen, H M. (1967) Adv. Enzyme. Regul. 5, 335-56. 
28.  Purich, D L; Fromm, H J; Rudolph, F B. (1973) Adv. Enzymol. Relat. Areas. Mol. Biol. 39, 
249-326.  
29. Rose, I A; Warms, J V. (1967) J. Biol. Chem. 242, 1635-45.  
30. Azoulay-Zohar, H; Israelson, A; Abu-Hamad, S; Shoshan-Barmatz, V. (2004) Biochem. J. 
377, 347-55. 
31. Lindén, M; Gellerfors, P; Nelson, B D. (1982) FEBS Lett. 141, 189-92.  
32. Fiek, C; Benz, R; Roos, N; Brdiczka, D. (1982) Biochim. Biophys. Acta. 688, 429 40. 
33. Beutner, G; Ruck, A; Riede, B; Welte, W; Brdiczka, D. (1996) FEBS Lett. 396, 189-95.  
34. Beutner, G; Rück, A; Riede, B; Brdiczka, D. (1997) Biochem. Soc. Trans. 25, 151-7.  
35. Vyssokikh, M Y; Brdiczka, D. (2003) Acta. Biochim. Pol. 50, 389-404.  
36. Vyssokikh, M Y; Goncharova, N Y; Zhuravlyova, A V; Zorova, L D; Kirichenko, W; 
Krasnikov, B F; Kuzminova, A E; Melikov, K C; Melik-Nubarov, N S; Samsonov, A V; 
Belousov, W; Prischepova, A E; Zorov, D B. (1999) Biochemistry (Mosc). 64, 390-8.  
37. Machida, K; Ohta, Y; Osada, H. (2006) J. Biol. Chem. 281, 14314-20. 
10 
 
38. Crompton, M; Virji, S; Doyle, V; Johnson, N; Ward, J M. (1999) Biochem. Soc. Symp. 66, 
167-79.  
39. Zamzami, N; Kroemer, G. (2003) Curr. Biol. 13, R71-3.  
40. Lemasters, J J; Qian, T; Bradham, C A; Brenner, D A; Cascio, W E; Trost, L C; Nishimura, 
Y; Nieminen, A L; Herman, B. (1999) J. Bioenerg. Biomembr. 31, 305-19.  
41. Shimizu, S; Narita, M; Tsujimoto, Y. (2000) Nature 399, 483-87.  
42. Shimizu, S; Matsuoka, Y; Shinohara, Y; Yoneda, Y; Tsujimoto, Y. (2001) J. Cell Biol. 152, 
237-50.  
43. Zaid, H; Abu-Hamad, S; Israelson, A; Nathan, I; Shoshan-Barmatz, V. (2005) Cell Death 
Differ. 12, 751-60.  
44. Abu-Hamad, S; Sivan, S; Shoshan-Barmatz, V. (2006) Proc. Natl. Acad. Sci. U S A. 103, 
5787-92.  
45. Shoshan-Barmatz, V; Zakar, M; Rosenthal, K; Abu-Hamad, S. (2009) Biochim. Biophys. 
Acta. 1787, 421-30. 
46.Robey R B; Hay N. (2005) Cell Cycle 4, 654-658. 
47.Neumann D; Bückers J; Kastrup L; Hell S W; Jakobs S. (2010) PMC Biophys. 3, 1-15 
48.Perevoshchikova I V; Zorov S D; Kotova E A; Zorov D B; Antonenko Y N. (2010) FEBS 
Lett. 584, 2397-2402. 
49.Arzoine L; Zilberberg N; Ben-Romano R; Shoshan-Barmatz V. (2009) J. Biol.Chem. 284, 
3946-3955. 
50.Yehezkel G; Hadad N; Zaid H; Sivan S; Shoshan-Barmatz V. (2006) J. Biol. Chem. 281, 
5938-5946. 
51.Yehezkel G; Abu-Hamad S; Shoshan-Barmatz V. (2007) J. Cell. Physiol. 212, 551-561 
52.Aleshin A E; Fromm H J; Honzatko R B. (1998) FEBS Lett. 434, 42-46. 
53.Estabrook R W, Holowinsky A. (1961) J. Biophys. Biochem. Cytol. 9, 19-28. 
54.Hiller S; Garces R G; Malia T J; Orekhov V Y; Colombini M; Wagner G. (2008) Science 
321, 1206-1210 
55.Bayrhuber M; Meins T; Haeck M; Becker S; Giller K; Villinger S; Vonrhein C; Griesinger C; 
Zweckstetter M; Zeth K. (2008) PNAS. 105(40), 15370-15375 
56.Tsay, J T; Oh, W; Larson, T J; Jakowski, S; Rock, C O. (1992) J. Biol. Chem. 267, 6807-14. 
11 
 
57.Clough, R C; Matthis, A L; Barnum, S R; Jaworski, J G. (1992) J. Biol. Chem. 267, 20992-
998. 
58.Volpe, J J; Vagelos, P R. (1976) Physiol. Rev. 56, 339-417. 
59.Greenspan, M D; Birge, C H; Powell, G; Hancock W S;Vagelos, P R. (1970) Science 170, 
1203-1204.  
60.Magnuson, K; Jackowski, S; Rock, C O; Cronan, J E Jr. (1993) Microbiol. Rev. 57, 522-
5542. 
61.Heath, R J; Rock, C O (1996) J. Biol. Chem. 271, 10996-11000. 
62.Omura, S. (1979) Bacteriol. Rev. (1979) 40, 681-697. 
63.Blatti, J L; Michaud, J; Burkart, M D. (2013) Curr. Opin. Chem. Biol. 17, 496-505. 
64.Howard, T P; Middelhaufe, S; Moore, K; Edner, C; Kolak, D M; Taylor, G N; Parker D A; 
Lee, R; Smirnoff, N; Aves, S J; Love, J. (2013) Proc. Natl. Acad. Sci. U.S.A. 110, 7636-41.    
65.Davies, C; Heath R J; White, S W; Rock, C O. (2000) Structure 8, 185-195. 
66.Qiu, W; Janson, C A; Konstantinidis, A K; Nwagwu, S; Silverman, C; Smith, W W; 
Khandekar, S; Lonsdale, J; Abdel-Meguid, S S. (1999) J. Biol. Chem. 274(51), 36465-71. 
67.Qiu, X; Janson, C A; Smith, W W; Head M; Lonsdale J; Konstantinidis A K. (2001) J. Mol. 
Biol. 307, 341-56. 
68.Gajiwala, K S; Margosiak, S; Lu, J; Cortez, J; Su, Y; Nie, Z; Appelt, K. (2009) Febs Lett. 
583, 2939-46.  
69.Misra, N; Patra, M C; Panda, P K; Sukla, L B; Mishra B K. (2013) J. Biomol. Struct. Dyn. 
31(3), 241-57. 
70. Khandekar, S S; Gentry, R D; Van Aller, S G; Warren, P; Xiang, H; Silverman, C; Doyle, L 
M; Konstantinidis, K A; Brandt, M; Daines, A R; Lonsdale, T J. (2001)  J. Biol. Chem. 276(32), 
30024-30. 
 
12 
 
CHAPTER 2. MECHANISM OF ATP-DEPENDENT RELEASE OF WILD-TYPE AND 
MUTANT HUMAN BRAIN HEXOKINASES FROM MITOCHONDRIA1 
A paper to be submitted to the Journal of Biological Chemistry 
Nimer Mehyar2, Muneaki Watanabe2, Lu Shen2, Andrew D. Skaff2, and Richard B. Honzatko2,3 
From the Roy J. Carver Department of Biochemistry, Biophysics and Molecular Biology 
Iowa State University, Ames, IA 50011 
Running title: Human brain HK release from mitochondria 
Keywords: human brain hexokinase, VDAC1, mitochondria, apoptosis, nucleotides  
Background: Hexokinase I binding to mitochondrion prevent apoptosis in the cells. Adenosine 
5’-triphosphate (ATP) releases HKI from mitochondria. 
Results: ATP and fluorescent nucleotide analogue 2’,3’-O-(2,4,6-trinitro-phenyl) adenosine 5’- 
diphosphate (TNP-ADP) release wild-type Hexokinase I, mHKI and N-domain from 
mitochondrion. TNP-ADP does not bind to N-domain HKI. TNP-ADP binds to VDAC1. 
Conclusion: ATP releases HKI from mitochondria by binding to VDAC1 on OMM. 
Significance: Propose a mechanism for nucleotide induced release of brain of HKI from 
mitochondria. 
 
ABSTRACT 
Adenosine 5’-triphosphate (ATP) can release hexokinase I (HKI) from its binding site on 
the outer mitochondrial membrane, but the mechanism of ATP release of HKI from 
mitochondria is unclear. ATP binds to the C-terminal half of HKI as a substrate and to the N-
terminal half near the membrane binding element. ATP may also bind to the voltage dependent 
anion channel (VDAC), the integral membrane component that putatively targets HKI to the 
mitochondrion. The fluorescent nucleotide analogue 2’,3’-O-(2,4,6-trinitrophenyl) adenosine 5’-
diphosphate (TNP-ADP) binds with high affinity to the C-terminal half of HKI (Kd = 2.8 ± 0.4 
μM) and to VDAC (Kd = 1.3 ± 0.1 μM), but not to the N-terminal half of HKI (Kd not available). 
                                                            
1 This research was supported in part by National Institute of Health Research Grant 
NS 10546. 
2 Graduate student and professor, respectively, Department of Biochemistry, Biophysics and 
Molecular Biology, Iowa State University. Research conducted and manuscript written by 
Mehyar with assistance from Muneaki, Shen, Skaff and Honzatko. 
3 To whom correspondence should be addressed. 
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ATP competes with TNP-ADP for binding sites on HKI (KA = 46 ± 6 μM) and VDAC (KA = 
550 ± 40 μM), but CTP does not displace TNP-ADP from either HKI or VDAC. Other 
trinitophenyl nucleotides (TNPATP, TNP-AMP, and TNP-CTP) bind with high affinity to HKI 
and VDAC. ATP and trinitrophenyl nucleotides individually release wild-type HKI from 
mitochondria; however, CTP is ineffective as an agent of release. ATP and ADP-TNP release the 
truncated N-domain of HKI from mitochondria, excluding nucleotide binding to either the N- or 
C-half of HKI in the release mechanism. Results here are consistent with a release mechanism 
caused by the binding of ATP or TNP-ADP to VDAC. 
INTRODUCTION 
Mammalian tissue contains four hexokinase isozymes: I, II, III and IV (1). Hexokinase I 
(HKI) or brain hexokinase has long been recognized as the “pacemaker of glycolysis” in brain 
tissue and the red blood cell (2). Human brain comprises less than 2% of body weight and yet it 
utilizes at least one-quarter of the circulating blood glucose and approximately one-fifth of the 
oxygen consumed by the body (3). Nevertheless, HKI is at least 95% inhibited under normal 
physiological conditions in brain tissue (2). A number of ligands inhibit HKI; however, glucose 
6-phosphate (Glc-6-P) is probably the primary physiological inhibitor of the Type-I enzyme (4). 
On the other hand, inorganic orthophosphate (Pi) is capable of ameliorating Glc-6-P inhibition 
under normal physiological conditions (5), although at elevated levels it inhibits HKI by binding 
to the active site (6). Hexokinase II (HKII) is functionally similar to HKI; however, Pi does not 
relieve Glc-6-P inhibition of the Type-II isozyme (7).  
HKI and HKII have evolved by the duplication and fusion of a primordial hexokinase 
gene similar to that of yeast hexokinase (8). Each half of HKI and HKII exhibits significant 
sequence similarities (9). For HKII both halves support catalysis and are each sensitive to 
inhibition by Glc-6-P (10), whereas only the C-terminal half of HKI supports activity (11). 
Nonetheless, both halves of HKI can bind Glc-6-P with high affinity, and moreover the binding 
of Glc-6-P to either half inhibits activity (12, 13). Pi binds with high affinity to the N-terminal 
half of HKI (14-15), and relieves Glc-6-P inhibition by an allosteric mechanism that couples 
both halves of the enzyme (15). 
HKI and HKII associate with the outer mitochondrial membrane in brain tissue (16). This 
interaction requires fifteen, largely hydrophobic amino acid residues at its N-terminus (17). HKI 
14 
 
association with outer mitochondrial membrane allows preferential access to newly formed 
mitochondrial ATP (16). HKI likely interacts with the voltage-dependent anion channel (VDAC) 
of the outer mitochondrial membrane (18-19). HKI binding to the mitochondrion prevents the 
opening of the permeability transition pore (PTP) (20). The PTP is a multicomponent system that 
includes the adenylate translocator (ANT) of the inner mitochondrion membrane, and the voltage 
dependent anion channel (VDAC) of the outer mitochondrion membrane (18-24), and is 
regulated by cyclophilin D of the inner mitochondrion matrix and the binding of hexokinase I 
and II (25-27). Opening of the PTP results in loss of membrane potential, organelle swelling, 
cytosolic acidification, and the release of cytochrome c (20, 25). Cytochrome c that escapes the 
mitochondrion after the PTP opening activates the caspase family of proteases, which ultimately 
results in apoptosis (27-29). 
Others maintain that the opening of the PTP initiates necrosis, but not apoptosis, and that 
a proapoptotic protein such as Bax, triggers the release of cytochrome c without mitochondrial 
swelling (25,30-31). Nevertheless, mitochondrion associated hexokinase II clearly antagonizes 
the action of pro-apoptotic factors such as Bax (32-34). Pro-apoptotic proteins (Bax, Bak, and 
Bim) interact with VDAC in the assembly of large pores that presumably serve as conduits for 
the release of cytochrome c (30-31,35). Indeed, overexpression of VDAC-1 causes apoptotic cell 
death (36-37). Hexokinase I and II, through their own associations with VDAC, may antagonize 
the formation of apoptotic channels. Some have gone so far as to label hexokinase as “guardian 
of the mitochondria” (38). Hexokinase co-localizes differentially with human VDAC1, 2 and 3 
(39). Hexokinase binding to mitochondria inhibits ATP flux through VDAC-1 (40). Over 
expression of N-terminally truncated VDAC-1 did not induce cells to release cytochrome c and 
the cells were resistant to apoptosis (41). The N-terminal peptide of VDAC-1 and other VDAC-1 
based peptides bind to immobilized HKI. These peptides prevented protection of cells by HKI 
(42). Chemical modification of Glu 72 eliminated the binding of HKI to mitochondria (36). 
Mutating Glu 72 and other residues abolished overexpressed HKI protection against apoptosis in 
different cancer cells (43). Adding HKI to VDAC-1 reconstituted in lipid membrane reduced the 
channel conductance (20). HKI addition to mutant (Glu 72 to glutamine) mouse VDAC 
reconstituted in lipid membrane did not lessen channel conductance, indicating failure of HKI to 
bind to mutant VDAC-1 (43).  
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A number of small and physiological important ligands are capable of dissociating HKI 
from the mitochondrial outer membrane. These compounds include Glc-6-P and ATP (16). Skaff 
et al. (44) demonstrated a wild-type recombinant HKI with properties comparable to native brain 
hexokinase, including those of mitochondrial binding and release. Their recombinant construct 
has an intact membrane targeting element and a formyl group attached to the amino terminus of 
the polypeptide chain. The release properties of mutant constructs demonstrated the significance 
of Glc-6-P binding to the N-terminal half of HKI in promoting the release of the mitochondrion 
associated enzyme. The Glc-6-P release phenomenon adheres to a simple equilibrium model. To 
date, little is known regarding the mechanism of ATP-induced release of HKI from mitochondria 
(16, 45-47). Three binding sites exist on HKI for adenine nucleotides: the active site at the C-
terminal half (11), the Pi binding site at the N-terminal half at which the nucleotide may bind 
through its terminal phosphoryl group (48), and the nucleotide pocket of unknown function near 
the N-terminal membrane targeting element (48-49). Photoactive ATP analog, Bz-ATP 
(benzoylbenzoyl-ATP), can bind to more than one sites on VDAC-1 with low and high affinities 
(50). Mutating residues in predicted nucleotide-binding site in VDAC-1 reduced ATP cellular 
levels and caused retarded cell growth (51). 
The purpose of the present study was to investigate the mechanism of HKI release from 
mitochondria by adenosine nucleotides, and which, if any, of the adenine nucleotide binding sites 
of HKI or VDAC are responsible for that release. The fluorescent ADP analog, 2’,3’-O-(2,4,6-
trinitrophenyl) adenosine 5’-diphosphate (TNP-ADP), binds with high affinity to single sites at 
the C-terminal domain of HKI and to VDAC. Nevertheless, TNP-ADP releases the N-terminal 
domain of HKI (a domain to which it does not bind) from mitochondria. The data here are 
consistent with a site on VDAC that binds HKI and ADP-TNP in a mutually exclusive manner. 
 
EXPERIMENTAL PROCEDURES 
Materials— ATP, ADP, chloramphenicol, deoxyribonuclease (DNase I), bovine serum 
albumin (BSA), leupeptin, protease cocktail inhibitor and phenylmethylsulfonyl fluoride came 
from Sigma. Kanamycin sulfate and 2’,3’-O-(2,4,6-trinitrophenyl)-derivatives of ATP, ADP, 
AMP, and CTP came from Invitrogen. DEAE HPLC was from Tosoh. Nickel-nitrilotriacetic 
acid-agarose (NiNTA) and Rosetta (DE3) competent cells were from Novagen. Glucose-6-
phosphate dehydrogenase was obtained from Roche Molecular Biochemicals. Isopropyl-1-thio-
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β-D-galactopyranoside (IPTG) came from Anatrace. His-tag anitbodies, N-terminal HKI 
antibodies and C-terminal HKI antibodies were from Abcam. Substrates for the 3,3’,5,5’-
tetramethylbenzidine enzyme-linked imunoabsorbant assay (TMB-ELISA) and western blotting 
chemiluminescence came from Pierce. Oligonucleotides came from the Iowa IDT. 
Lauryldimethylamine-N-oxide (LADO) was purchased from Affymetrix.  
Construction of Wild-type Hexokinase and N domain Plasmids— Human brain 
hexokinase (HKI) was cloned into pET-24b vector with a 10-residue histidine tag at its C-
terminus (pET-24b-HKI-10xHis) as reported previously (44). Hexokinase mutants were created 
through PCR modification. An NdeI cut site was created at Ala454 in pET-24b-HKI-10xHis 
using the forward primer, 5’-GCAGCGGCAAGGGGGCTCATATGGTGACGGCGGTGGC-3’, 
and its reverse complement. Mutant plasmid was digested with NdeI and then ligated to produce 
pET24b-N-C half-HKI-10xHis. This plasmid encodes residues 454-917 of HKI with a C-
terminal polyhistidyl tag (hereafter mHKI). An EcoRI cut site was created at Ala454 in pET-
24b-HKI-10xHis using the forward primer, 
5’GCAGCGGCAAGGGGGCTCGAATTCGTGACGGCGGTGGC-3’, and its reverse 
complement. Mutant plasmid was digested with NdeI and then ligated to produce pET24b-
NHKI-10xHis. This plasmid encodes residues 1-454of HKI with a C-terminal polyhistidyl tag 
(hereafter N domain HKI). 
Mitochondrion Purification— Pig livers were obtained from the Iowa State University 
Meats Laboratory shortly after slaughter. Mitochondrial purification is described (52) with 
modification as discussed elsewhere (44). Both outer mitochondrial membrane (OMM) and inner 
mitochondrial membrane (IMM) integrities were measured as described previously (53-54). 
Mitochondria were stored at –80º C in the presence of 5% dimethyl sulfoxide. 
Expression and Purification of Wild-Type HKI and N-domain HKI— E.coli strain Rosetta 
(DE3) cells were transformed with wild-type or N-domain HKI plasmids. Expression and 
purification HKI enzymes are discussed in detail by Skaff et al (44). The determination of 
protein concentration employed the Bradford method with bovine serum albumin as a standard 
(55). 
HKI Activity Assay— Hexokinase activity was measured using the glucose 6-phosphate 
dehydrogenase (G6PDH)-coupled spectrophotometric assay. All assay solutions had 3mM 
MgCl2, 3 mM DTT, 0.3 mM NADP, 10 μg/mL G6PDH and 50 mM Tris-HCl, pH 8.0. 
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Concentrations of substrate (either glucose or ATP:Mg2+ at1:1 ratio) varied from 1/5 to 5 times 
Km. NADPH production was monitored at 340 nm. G6PDH was in sufficient excess so that a 
doubling of HKI concentration resulted in a doubling of initial velocity. Assays were initiated by 
addition of 0.5 µg HKI. Initial rates were determined from slopes of linear progress curves 
(monitored for 3 minutes). Initial-rate data were analyzed using the GraFit computer program 
(56). The mechanism of TNP-ADP inhibition was determined by assays in the presence of 
saturating glucose (1.6 mM) and systematic variations in the concentration of ATP:Mg2+ at1:1 
(0.3-4.5 mM) and TNP-ADP (0-40 μM). Mitochondrion-bound hexokinase was added to the 
assay cocktail with saturating glucose (1.6 mM) and saturating ATP:Mg2+, 1:1 (6 mM). Initial 
velocity data were fit to models described in the Results section by nonlinear least squares using 
GraFit (56). 
Mitochondrial Binding and Release— Purified HKI was dialyzed twice against 
mitochondrial binding buffer (250 mM sucrose, 5 mM Glc, 50mM NaCl, 5 mM MgCl2 and 50 
mM HEPES, pH7.4), and then diluted to 2 mg/mL using the same buffer. Thirty mg wet weight 
of mitochondrion (0.24 mg mitochondrial protein), thawed on ice, was suspended in 1 mL of 
mitochondrial-binding buffer, and then collected by centrifugation at 11,000 × g for 5 minutes. 
Suspension and centrifugation steps were repeated twice. The pellet was suspended in 1 mL of 
mitochondrial binding buffer with added HKI (2 mg/mL), protease cocktail inhibitor (0.25 
mg/mL) and PMSF (1 mM). After 60 minutes on ice, the mixture of HKI and mitochondria was 
centrifuged at 11,000 × g for 5 minutes. Unbound HKI in the supernatant fluid was decanted. 
Pelleted mitochondria were suspended in mitochondrial binding buffer, less the MgCl2, NaCl, 
and Glc, and centrifuged again. This wash step was twice repeated. HKI-bound mitochondria, 
prepared as above, is suspended in release buffer (250 mM sucrose and 50 mM HEPES, pH 7.4). 
One hundred μL aliquots of this suspension were distributed to plastic micro-centrifuge tubes, to 
which were added a release agent (ATP or TNP-nucleotide) at various concentrations. After 30 
minutes at room temperature, the mitochondria were pelleted by centrifugation. HKI solubilized 
by nucleotide was removed by decanting the supernatant liquid. The mitochondrial pellet was 
suspended in wash buffer (250 mM sucrose and 5 mM HEPES, pH 7.4), and centrifuged. After 
discarding the supernatant fluid, pelleted mitochondria were suspended in 100 μL wash buffer 
and then assayed for hexokinase activity or suspended in 100 μL of coating buffer (100 mM 
sodium carbonate/bicarbonate, pH 9.6) for ELISA assays. 
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HKI ELISA Assay— Fifty μL of HKI-bound mitochondrial suspension in coating buffer 
(100mM Na2CO3/NaHCO3 pH 9.6) was loaded in each well of the ELISA plate and incubated 
overnight at 4 C. Plates were washed four times with PBST (137mM NaCl, 2.7mM KCl, 8.1mM 
Na2HPO4, 1.76mM KH2PO4, pH 7.4, 0.05% Tween-20). Wells were blocked with 200 μL of 1% 
BSA in PBST at room temperature for 2 hours and then washed four times with 200 μL PBST. 
Wells were incubated with 100 μL of anti-His-tag primary antibodies (1:1000 dilution) for 2 
hours at room temperature, and then washed four times with PBST. One hundred μL of anti-
rabbit IgG secondary antibodies solution (1:10000 dilution) was added to each well, incubated 
for 2 hours at room temperature, and then washed four times with PBST. A volume of 100 μL of 
1-Step Ultra TMB-ELISA solution was added to each well. A Biotek (Ceres 900) plate reader 
was used to measure change in absorbance at wavelength 620 nm. A reading was taken every 10 
seconds, a total of 75 for each well. HKI was used as a positive control and mitochondria as a 
negative control. Slopes of linear progress curves were determined by regression analysis, and 
used in nonlinear least square fits (using GraFit) to models described in the Results section. 
Mitochondria western blotting— Mitochondria with and without bound HKI were re-suspended 
in 15 μL water plus 3μL of loading buffer (1M Tris-HCl, pH 6.8, 10% SDS, 3% glycerol, 0.12 
mg/mL bromophenol blue) and boiled for 5 minutes prior to polyacrylamide gel electrophoresis 
(SDSPAGE). After removal of SDS, proteins were transferred by blotting from gel to 
nitrocellulose membranes (57). Membranes were blocked with 3% bovine serum albumin in 50 
mM Tris, 150 mM NaCl, 0.05% Tween 20, pH 7.6, (TBST buffer) for one hour at room 
temperature and then washed three times with TBST buffer. Membranes were exposed to 
primary antibody (His-Tag antibodies, C-terminal HKI antibodies, or N-terminal HKI 
antibodies) in TBST buffer for one hour at room temperature, and then washed three times with 
TBST buffer. Membranes were subsequently treated with rabbit IgG secondary antibodies for 
one hour at room temperature and washed three times with TBST buffer. Finally, x-ray film was 
exposed for 1 minute to membranes treated with Pierce chemiluminescence substrate and then 
developed. 
Cloning of Wild-type human VDAC-1— A plasmid with the coding sequence of human 
VDAC-1 (hVDAC-1) was purchased from Open Biosystems. NdeI and SacI cut sites were 
created in the plasmid using the polymerase chain reaction (PCR) and NdeI primer 
5'CGCGGCAGCCATATGATGGCTGTGCCACCCACG3' and SacI primer 
19 
 
5'GGACTGGAATTTCAAGCA TCGAGCTCCGTCGACAAGC3'. The PCR product and vector 
pET-24a were digested by NdeI and SacI restriction enzymes. After separation on agarose gel, 
the DNA fragment for hVDAC-1 was ligated to pET-24a. The construct was confirmed by DNA 
sequencing facility at Iowa State University. 
Expression and purification of hVDAC-1— Wild-type human VDAC-1 containing 
plasmid was transformed into E. coli strain BL21 (DE3). Cells were grown in LB media at 37 °C, 
kanamycin was added to a final concentration of (30 μg/mL). Growth was monitored by 
absorbance at wavelength 600 nm. At A600 of 0.9, the temperature was reduced to 16 °C and 
IPTG was added to a final concentration of 0.3 mM. Cells were collected after 16-20 hours of 
induction and suspended in lysis buffer (30mM Tris-HCl, pH8.0, 150mM NaCl, 1mM EDTA, 
and 1mM DTT). DNase (50 μg/mL), leupeptin (5 μg/mL), and PMSF (1 mM) were all added to 
the solution. Cells were lysed by sonication. Inclusion bodies were pelleted at 32460g for 1 hour. 
Pelleted inclusion bodies were subjected to the following procedures three times: separation from 
the supernatant fraction, suspension in wash buffer (30 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 
mM EDTA, 1 mM DTT) and centrifugation at 15,000rpm 32460g for 30 minutes. Inclusion 
bodies were suspended in 30 mL of wash buffer plus 1% Triton X-100, incubated for 30 minutes 
at 37 °C, and then suspended and washed twice with wash buffer.  
Refolding of Wild-Type Human VDAC1— Human VDAC1 purification and folding 
follows protocols in the literature (51, 58) with modifications. Washed inclusion bodies were 
solubilized in 150 mL dissolving buffer (6M guanidine hydrochloride, 10 mM DTT, 0.1 mM 
EDTA, 100 mM Tris-HCl, pH8.0) to a final protein concentration of 15 mg/mL. Inclusion bodies 
dissolved completely in 12 hr. at 4 °C. Twenty five milliliters of unfolded human VDAC-1were 
diluted by slow addition into 300 mL of refolding buffer (0.1 mM EDTA, 1 mM DTT, 100 mM 
Tris-HCl, pH8.0, 2% LDAO) at 4 °C. Refolded protein was concentrated and dialyzed against 50 
mM Tris-HCl. pH 7.5, 0.1% LDAO buffer for 24 hr at 4 °C. Solution was loaded onto a nickel-
nitrilo triacetic acid (Ni-NTA) column. The column was washed with buffers containing 50 mM 
Tris-HCl, pH7.5, 300 mM NaCl, 0.1% LDAO and 5 mM imidazole and then 50 mM imidazole. 
Finally, human VDAC-1 was eluted with the same buffer containing 300 mM imidazole. 
HKI and VDAC-1 Fluorescence Experiments— Purified HKI and human VDAC-1 were 
dialyzed against 2 mM glucose and 50 mM Tris-HCl, pH 7.5. Fluorescence measurements were 
made at room temperature using a 1-cm2 quartz cuvette on a SLM Amico 8000 fluorimeter with 
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entrance/exit slits of 4 mm in the presence of 10% polyethyleneglycol, MW ~10,000 (PEG) in 
the case of HKI. For TNP-nucleotides the excitation wavelength was 409 nm, and emission scans 
were from 450 to 600 nm. Fluorescence scans (a total of three for each datum) were performed 
after additions of small volumes of TNP-nucleotide to 2mL of 2.5μM HKI or human VDAC-1. 
TNP-nucleotide displacement was accomplished by the addition of the alternative nucleotide to 1 
mL solution of 2 .5 μM HKI or human VDAC-1 and 1 μM TNP-nucleotide. For each kind of 
experiment, the total concentration of added titrant did not exceed 5% of the initial volume of 
solution, and the total concentration of titrant was corrected for volume changes. The analysis of 
fluorescence data followed the approach of Fallar (59), modified as described in the Results 
section, using GraFit to perform nonlinear least squares fitting. 
RESULTS 
Mitochondria integrity and absence of native hexokinase— Cytochrome c oxidase 
activity indicated 90% integrity of OMM (data not shown). Uptake of carbocyanine dye JC-1 
indicated intact IMM (data not shown). Western blotting of pig liver mitochondria and staining 
with polyclonal antibodies raised against HKI indicated the absence of native hexokinase (data 
not shown). 
TNP-ADP inhibits HKI— Wild-type HKI (kcat = 73 ± 4 s-1, Km Glc = 77 ± 6 μM, Km 
ATP = 1.1 ± 0.1μM) exhibited no measurable activity with TNPADP as a replacement substrate 
for ATP, placing an upper limit on kcat of 0.001 s-1. TNP-ADP has no effect on the activity 
glucose 6-phosphate dehydrogenase (coupling enzyme) up to a concentration of 100 μM. On the 
other hand, TNP-ADP is a competitive inhibitor with respect to ATP (Ki = 4.9 ± 0.5 μM) (Fig.1). 
TNP-nucleotide binding to Wild-type hexokinase I and displacement by ATP— The observed 
fluorescence from a mixture of TNP-ADP and HKI comes from free TNP-ADP, TNP-ADP 
bound to HKI, and HKI itself: Fobs  =  Ffree  +  Fbound  +  Fprotein (1) 
Fprotein is small relative to other contributions as HKI has no native fluorophore sensitive to an 
excitation wavelength of 409 nm. Ffree=a + b[L] +c[L]2, where a, b, and c are determined by a fit 
of fluorescence versus [L] in the absence of protein under buffer conditions identical to those 
used in the titration of HKI. Fbound = γb(L0 – [L]), where γ is a fluorescence enhancement factor 
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of the bound relative to the free state of the fluorescent ligand and Lo and [L] are the total and 
free concentrations of fluorescent ligand.  
A single binding-site model adequately accounts for the observed fluorescence of the bound state 
 
 
FIGURE 1. TNP-ADP and ATP binding to WTHKI. TNP-ADP inhibition of HKI competitive 
with ATP HKI activity was measured using the Glc-6-P dehydrogenase assay in 100 mM Tris, 
pH 8.0, glucose 1.6 mM, ATP 0.3-4.5 mM and TNP-ADP 0 µM (●), TNP-ADP 2.5 µM 
(□),TNP-ADP 10 µM (▲),TNP-ADP20 µM (■), and TNP-ADP 40 µM (▲). 
 
and for the displacement of the TNP-nucleotide by a non-fluorescent nucleotide: 
𝑃𝑃 + 𝐿𝐿 = 𝑃𝑃𝐿𝐿,       𝐾𝐾𝐿𝐿 = [𝑃𝑃][𝐿𝐿][𝑃𝑃𝐿𝐿]  
𝑃𝑃 + 𝐴𝐴 = 𝑃𝑃𝐴𝐴,      𝐾𝐾𝐴𝐴 = [𝑃𝑃][𝐴𝐴][𝑃𝑃𝐴𝐴]  
Scheme I 
In Scheme I, L represents the TNP-nucleotide and A the displacing ligand. The equilibrium 
relationships of Scheme I with mass conservation relationships for L0 (total fluorophore 
concentration), A0 (total concentration of displacing ligand) and P0 (total concentration of 
protein) leads to a third-order equation in the concentration of free protein [P]. For circumstances 
here, KA >> [P], allowing an approximation that reduces the third order equation to one of 
second order: 
 �1 + 𝐴𝐴0
𝐾𝐾𝐴𝐴
� × [𝑃𝑃]2 + �𝐾𝐾𝐴𝐴−𝑃𝑃0+𝐴𝐴0𝐾𝐾𝐿𝐿
𝐾𝐾𝐿𝐿+𝐿𝐿0
� × [𝑃𝑃]2 − 𝑃𝑃0𝐾𝐾𝐿𝐿 = 0 (2) 
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The physical root of this quadratic relationship is the concentration of free protein, and 
determines the concentration of free fluorophore [L] = L0KL / (KL + [P]) at a given total 
concentration of fluorophore, L0. GraFit software optimizes the fit of the observed fluorescence 
to the right-hand side of Eq. 1 at fixed P0 and varying Lo and Ao by adjusting parameters KA, KL, 
γ and Fprotein. TNP-ADP binds with high affinity to wild-type HKI (KL = 2.8 ± 0.4 μM, γ = 6.0 
± 0.2, and Fprotein = 0.13 ± 0.03) and to mHKI (KL = 5.2 ± 1.5 μM, γ = 3.2 ± 0.3, and Fprotein = 
0.03 ± 0.01), however; it binds weakly to the N-domain of HKI (KL , not available) (Fig. 2). ATP 
displaces TNP-ADP from wild-type hexokinase (KA = 46 ± 6 μM) (Fig. 3) and mHK (KA = 97 ± 
19 μM) (data not shown). 
 
 
FIGURE 2. Titration of HKI constructs with TNP-ADP. Plots represent the fluorescence at 
varying total concentrations of TNP-ADP in 2 mM glucose, 10% PEG (MW ~10,000) and 50 
mM Tris-HCl, pH 7.5, with no protein (▲),wild-type HKI 2.5 μM (○),mHKI 2.5 μM (●) 
and N-domain HKI 2.5 μM (●). Black lines for wild-type HKI, mHKI and N-domain HKI 
represent Eq. 1 with Ao of 0 μM, Po of 2.5 μM and parameters KL, KA, γ and Fprotein given in 
the Results section. The gray line is the fit of observed fluorescence in the absence of protein to 
the second-order polynomial, a + b(Lo) + c(Lo)2. 
 
TNP-nucleotide binding to wild-type human VDAC-1 and displacement by nucleotides— 
Single binding site model of Scheme I also account for TNP-ADP binding to VDAC-1 and its 
displacement by ATP. Analog TNP-ADP binds to VDAC-1 with high affinity (KL = 1.3 ± 0.1 
μM, γ = 16.7 ± 0.3, Fprotein = 0.06 ± 0.02) (Fig. 4) and is displaced by ATP (KA = 550 ± 40 μM) 
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(Fig. 5). CDP does not displace TNP-ADP from VDAC-1 (Fig. 6). Analogs TNP-ATP, TNP-
AMP and TNP-CTP bind to VDAC-1 similarly to TNP-ADP (Table 1). 
 
FIGURE 3. Titration of wild-type HKI bound TNP-ADP with ATP. Plot represents the 
fluorescence at varying total concentrations of ATP (○) added to 2.5 μM wild-type HKI and 5 
μM TNP-ATP in 2mM glucose, 10% PEG (MW ~10,000) and 50 mM Tris pH 7.5. The solid line 
represents is a fitted curve using Eq. 1 with Lo of 5 μM, Po of 2.5 μM. 
 
 
FIGURE 4. Titration of wild-type human VDAC-1 with TNP-ADP. Plots represent the 
fluorescence at varying total concentrations of TNP-ADP in 2 mM glucose and 50 mM Tris-HCl, 
pH 7.5, with no protein (○) or with wild-type human VDAC-1 2.0 μM (●). The black line 
represents Eq.1 with Po of 2 μM, Ao of 0 μM and parameters KL, KA, γ and Fprotein given in 
the Results section. The gray line is the fit of observed fluorescence in the absence of protein to 
the second-order polynomial, a + b(Lo) + c(Lo)2. 
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FIGURE 5. Titration of wild-type human VDAC-1 bound TNP-ADP with ATP. Plot represents 
the fluorescence at varying total concentrations of ATP (○) added to 2.0 μM wild-type human 
VDAC-1 and 5 μM TNP-ATP in 2mM glucose and 50 mM Tris, pH 7.5. The black line 
represents Eq. 1 with Po of 2 μM, Lo of 5 μM. 
 
 
 
FIGURE 6. Human VDAC-1 bound TNP-ADP displacement by nucleotides. Fluorescence scans 
of 2.0 μM human VDAC-1 in 2mM glucose and 50 mM Tris, pH 7.5. human VDAC-1 only (○) , 
5µM ANP-ADP only (○), human VDAC-1 plus 5 μM TNP-ADP (●), human VDAC-1 plus 5 
μM TNP-ADP and 10mM ATP (▲), and human VDAC-1 plus 5 μM TNP-ADP and 10 mM 
CDP (▲). 
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TABLE 1. TNP-nucleotides binding to wild-type human VDAC-1. 
TNP-nucleotide KL (μM) γ Fprotein 
TNP-ATP 0.5 (2) 16.4 (9) 0.40 (9) 
TNP-ADP 1.3 (1) 16.7 (3) 0.06 (2) 
TNP-AMP 2.0 (1) 20.4 (3) 0.13 (2) 
TNP-CTP 0.7 (1) 11.2 (3) 0.22 (2) 
 Parameters are from a single binding site model. KL, γ and Fprotein are constants for the 
dissociation of TNP-nucleotides from human VDAC-1. Fluorescence was measured at varying 
total concentrations of TNP-nucleotides in 2 mM glucose and 50 mM Tris-HCl, pH 7.5. Standard 
deviations in the last significant digits are given in parentheses. 
 
Nucleotide release of wild-type HKI— Incubation times of twenty and sixty minutes 
produced identical release curves, indicating an equilibrium phenomenon. Scheme II represents 
the simplest equilibrium model that accounts for ATP release of wild-type and mutant enzymes 
from mitochondria. 
𝐸𝐸 + 𝑄𝑄 = 𝐸𝐸𝑄𝑄,     𝐾𝐾1 = [𝐸𝐸𝑄𝑄][𝐸𝐸][𝑄𝑄] 
𝐸𝐸 + 𝑃𝑃 = 𝐸𝐸𝑃𝑃,     𝐾𝐾2 = [𝐸𝐸𝑃𝑃][𝐸𝐸][𝑃𝑃] 
𝑄𝑄 + 𝐴𝐴 = 𝑄𝑄𝐴𝐴,     𝐾𝐾3 = [𝑄𝑄𝐴𝐴][𝑄𝑄][𝐴𝐴] 
Scheme II 
In Scheme II, K1 and K2 represent association constants for the binding of HKI (represented by 
E) to specific mitochondrial binding sites Q, and nonspecifically to the membrane at sites P. The 
association constant K3 represents the binding of A competitively with E for the specific binding 
sites Q. The fraction of E bound to mitochondria depends explicitly on the concentrations of Q 
and P, and implicitly on the concentration of A as follows: 
 𝑅𝑅([𝐴𝐴]) = 𝐾𝐾1[𝑄𝑄]+𝐾𝐾2[𝑃𝑃]
1+𝐾𝐾1[𝑄𝑄]+𝐾𝐾2[𝑃𝑃] = (𝐾𝐾1 [𝑄𝑄]+𝐾𝐾′2)1+𝐾𝐾1[𝑄𝑄]+𝐾𝐾′2 (3) 
The concentration of free nonspecific binding sites for hexokinase is overwhelmingly large 
allowing a pseudo constant K’2 to approximate the product K2[P]. The concentration of free 
specific mitochondrial sites Q is itself a function of the concentrations of enzyme and 
competitive binding ligand. Algebraic manipulation of the equilibrium expression in Scheme II 
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and relationships for mass conservation of total enzyme E0 and total specific sites Qo results in a 
quadratic relationship in Q: 
𝑎𝑎[𝑄𝑄]2 + 𝑏𝑏[𝑄𝑄] + 𝑐𝑐 = 0 
where a = K1(1 + K3[A]), b = K1(E0 - Q0) + (1 + K’2) (1 + K3[A]), and c = -Q0(1 + K’2). The 
general solution to the quadratic equation gives [Q]: [𝑄𝑄] =
−𝐾𝐾1(𝐸𝐸0−𝑄𝑄0)−�1+𝐾𝐾′2�(1+𝐾𝐾3[𝐴𝐴])+�𝐾𝐾12(𝐸𝐸0−𝑄𝑄0)+2𝐾𝐾1(𝐸𝐸0−𝑄𝑄0)(1+𝐾𝐾′2)(1+𝐾𝐾3[𝐴𝐴])+(1+𝐾𝐾′2)2(1+𝐾𝐾3[𝐴𝐴])2+4𝐾𝐾1(1+𝐾𝐾3[𝐴𝐴])𝑄𝑄0�1+𝐾𝐾′2�
2𝐾𝐾1(1+𝐾𝐾3[𝐴𝐴])
(4) 
Substitution of Eq. 4 into Eq. 3 provides a relationship for the fraction of enzyme bound to the 
mitochondria R([A]), explicitly as a function of [A]. 
The fitting relationship is: 
 𝑉𝑉 = 𝑠𝑠𝑅𝑅[𝐴𝐴] (5) 
where s is a proportionality constant that relates the fraction of bound enzyme R([A]) to velocity 
V in μmoles/min. Eq. 5 includes undefined quantities s, E0, Q0, K1, K’2 and K3; all six cannot be 
determined by a nonlinear least squares fit of data from a single experiment. Hence, values for 
some of these quantities must come from other determinations. Firstly, one assumes the HKI-
VDAC complex has an equal number of HKI and VDAC subunits. The value for Qo (7.1x10–8 
M) then is an estimate based on 42,000 VDAC molecules per mitochondrion (60), 7.2x109 
mitochondria per 1 mg of total mitochondrial protein (61), and 0.014 mg of mitochondria in each 
100 μL assay. In binding HKI to mitochondria, the concentration of enzyme (10-6 M) is 10-fold 
greater than the estimated concentration of specific binding sites. After washing away excess 
enzyme, we assume all specific sites have bound enzyme, and that the condition E0=Q0 applies to 
the system. The release of HKI is complete at the highest levels of nucleotide, R([A]→∞) = 0, 
which requires K’2 = 0. Moreover, s = Qo × (specific activity) × (assay volume), where the 
specific activity for HKI is 6x109 μmole/min-1 mole-1 and the assay volume is liters. Hence, if 
the assumption of a 1:1 ratio of the HKI-VDAC complex is correct, then data can be fit to Eq. 5 
using K1 and K3 alone as adjustable parameters. Moreover, as K1 represents the binding affinity 
of HKI for the mitochondrion, all experiments using wild-type HKI should provide comparable 
values for K1 regardless of the release agent. Listed in Table 2 are values for K1 and K3 for 8 
release experiments involving ATP and ADP. Although correlations in K1 and K3 are evident, 
27 
 
one finds values of K1 within a single order with an average value of 4.1 ± 1.0x108 M-1. In 
release experiments involving the HKI activity assay, K1 is set to its average value, and only K3 
is optimized in fitting the data. The true uncertainty in K3 then is on par with that for the average 
value of K1; however, on a comparative basis the K3 values in Table 3 accurately reflect the 
relative binding efficacies of nucleotides to VDAC. Characteristic release curves are in Fig. 7. 
All TNP-nucleotides tested were effective in the release of wild-type HKI from mitochondria. 
 
TABLE 2. ATP and ADP release of wild-type HKI from pig liver mitochondria in the 
determination of K1. 
 K1 (M
-1) K3ATP (M-1) K3ADP (M-1) 
Experiment 1 6.0 x 108 (1.2 x 108) 5.2 x 104 (1.7 x 104) - 
Experiment 2 5.1 x 108 (7.8 x 107) 4.9 x 104 (8.9 x 103) - 
Experiment 3 6.6 x 108 (2.4 x 108) 1.5 x 104 (6.1 x 104) - 
Experiment 4 8.1 x 108 (3.3 x 108) 1.7 x 105 (7.7 x 104)  
Experiment 5 1.3 x 108 (1.5 x 107) 3.6 x 104 (6.7 x 103)  
Experiment 6 1.2 x 108 (1.3 x 107) 3.7 x 104 (6.6 x 103)  
Experiment 7 2.7 x 108 (6.9 x 107) - 9.6 x 103 (3.7 x 103) 
Experiment 8 2.1 x 108 (4.4 x 107) - 8.5 x 103 (2.6 x 103) 
Parameters are from an equilibrium model in which the binding of nucleotide and WHKI and 
nucleotide to the mitochondrion is mutually exclusive. K1, K3ATP and K3ADP are constants for the 
association in M-1 of HKI, ATP and ADP from the mitochondrion. Mitochondria with HKI 
bound in 250mM sucrose and 50 mM HEPES, pH7.5, were exposed to different nucleotides for 
30 minutes. Remaining mitochondria bound HKI was measured by activity. Standard deviations 
in the last significant digits are given in parentheses. 
 
TABLE 3. Release of wild-type HKI from pig liver mitochondria by TNP-nucleotides. 
TNP-nucleotide K3 (M-1) 
ATP 9.9 x 104 (3.0 x 103) 
ADP 1.8 x 104 (3.5 x 103) 
TNP-ATP 2.7 x 105 (2.7 x 104) 
TNP-ADP 3.7 x 105 (5.2 x 104) 
TNP-AMP 3.1 x 105 (5.2 x 104) 
TNP-CTP 1.9 x 105 (4.8 x 104) 
Parameters are defined in the Results section and by Scheme II. K1 is set to its average value of 
4.1x108 M-1 and K3 determined by fitting Eq. 5 to data as described in the Results section. 
Standard deviations in the last significant digit are given in parentheses 
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Nucleotide induced release of N-domain HKI from mitochondria— Validation of the 
ELISA assay is provided by Fig. 8. Release of wild-type HKI, determined as a percent of total 
release, is measured comparably by the ELISA and the HKI activity assays. Measures of 
nucleotide affinity constants come from the fitting data to Eq. 5. The parameter s, however, is 
difficult to determine, requiring the optical path length of a plate reader, and the assumption of 
one to one  
 
FIGURE 7. Nucleotide-induced release of wild-type HKI from pig liver mitochondria. 
Mitochondria with HKI bound in 250 mM sucrose and 50 mM HEPES, pH 7.5, were exposed to 
different nucleotides for 30 minutes. Plots represent relative velocities from mitochondria-bound 
HKI that remains after exposure to varying concentrations of ATP (▲), TNP-ATP (○), or TNP-
ADP (●). The solid lines represent fitted curves using Eq. 5 with parameters given in Table 3. 
 
correspondences between the hexokinase construct, primary antibody, and secondary 
antibody/peroxidase components. Moreover, nonzero background levels in the presence of high 
concentrations of nucleotide require a nonzero K’2. Hence, fitting of data from ELISA assays 
employs s, K’2 and K3 as parameters. TNP-ADP and ATP release wild-type HKI and N-domain 
HKI from mitochondria to a comparable extent (Fig. 8), and provide values for 
K3 that compare favorably to those of the determined from the HKI assays (Table 4). 
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FIGURE 8. Nucleotides induced release of wild-type HKI and N-domain HKI from pig liver 
mitochondria measured by kinetic ELISA. Mitochondria with HKI bound in 250 mM sucrose 
and 50 mM HEPES, pH 7.5, were exposed to different nucleotides for 30 minutes. Plots 
represent wild-type HKI (●) or N-domain HKI (○) that remains bound to mitochondria as 
measured by His-Tag antibodies and ELISA. The solid lines represent fitted curves using Eq. 5 
with parameters given in Table 4. 
 
TABLE 4. Nucleotide-dependent release of HKI constructs from pig-liver mitochondria. 
HKI Construct Nucleotide s (μmol/min) K2′ (M-1) K3 (M-1) 
Wild-typea ATP 0.0213
* 0** 3.1 x 104 (2.9 x 103) 
TNP-ADP 0.0213* 0** 2.3 x 105 (6.8 x 104) 
Wild-typeb ATP 0.098 (3) 0.14 (3) 1.3 x 10
4 (8.2 x 103) 
TNP-ADP 0.110 (1) 0.24 (1) 1.8 x 105 (3.8 x 104) 
N-domainb ATP 0.190 (2) 0.44 (2) 2.8 x 10
4 (5.9 x 103) 
TNP-ADP 0.069 (1) 0.73 (2) 1.3 x 105 (4.1 x 104) 
Parameters are defined in the Results section and by Scheme II. K1 is set to its average value 
4.1x108 M-1 and s, K2' and K3 determined by fitting to Eq.5 to data as described in the Results 
section. Mitochondria with HKI bound in 250 mM sucrose and 50 mM HEPES, pH 7.5, were 
exposed to different nucleotides for 30 minutes. Remaining mitochondria bound HKI was 
measured by activity and/or ELISA. Standard deviations in the last significant digit are in 
parentheses. 
aMeasured by HKI activity 
bMeasured by His-tag antibodies and kinetic-ELISA 
* Calculated as described in the Results section 
** Fixed at zero as described in the Results section 
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DISCUSSION  
Previous reports demonstrated the release of HKI from mitochondria by ATP and other 
nucleotides at millimolar concentrations (16, 45-47). The importance of the hexokinase 
mitochondrion interaction to apoptosis motivated our efforts to quantify and determine the 
mechanism of nucleotide release of HKI from mitochondria. Four general mechanisms can 
account for ATP-release of HKI from mitochondria (Fig. 9): ATP binds to the C-terminal 
domain of HKI causing release. ATP and HKI bind with mutual exclusion to human VDAC-1. 
ATP binds to the N-terminal domain of HKI causing release. HKI converts ATP and glucose to 
Glc-6-P, which in turn binds to the N-terminal half of HKI triggering release.  
 
 
FIGURE 9. Four mechanisms by which ATP could release HKI from mitochondria. VDAC-1 
(cylinder) HKI (rectangles) interact directly. ATP binds to HKI, C-terminal half, (Mechanism I), 
to VDAC (Mechanism II), or to HKI, N-terminal half (Mechanism III) to disrupt the HKI-
VDAC-1 complex. HKI produces glucose 6-phosphate from ATP, which in turn binds to N-
terminal half of HKI (Mechanism VI) to disrupt the HKI-VDAC-1 complex. 
 
The experimental protocols adopted here avoid the combination of glucose and ATP, 
which in the presence of Mg2+ and HKI would result in the generation of Glc-6-P. TNP-
nucleotides are not substrates for HKI (current study) or for yeast hexokinase (62). TNP-ADP 
binds to HKI and yeast hexokinase at micromolar concentrations and is displaced by ATP. In the 
absence of Mg2+ both TNP-ADP and ATP release HKI from mitochondria. Under such 
conditions, the evolution of Glc-6-P from ATP and glucose is an unlikely cause for ATP release, 
and cannot be the mechanism by which TNP-ADP releases HKI from the mitochondrion 
(Mechanism IV).  
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A test of Mechanisms II and III requires an assay for N-domain HKI, which has no 
hexokinase activity. Data of Fig. 10 validate the kinetic ELISA assay to measure levels of N-
domain HKI bound to mitochondria. The kinetic ELISA measures the HKI construct in any state 
(active or inactive), whereas the HKI activity assay measures only HKI in an active state. The 
presence of substantial peroxidase activity in the presence of high levels of nucleotide indicates 
residual HKI bound to the mitochondrion. This bound fraction of HKI must not be active, as it 
would be detected by the HKI activity assay. Blank samples (mitochondria not exposed to an 
HKI construct) in the ELISA assay have low peroxidase activity, consistent with Western blots 
which indicate no bound HKI on the surface of the pig-liver mitochondria. Released HKI, as a 
fraction of total released HKI, is nonetheless in excellent agreement for the two assay methods 
(Fig. 10).  
 
FIGURE 10. Nucleotide release of wild-type HKI and N-domain HKI from pig liver 
mitochondria. Plots represent wild-type HKI (■) remained bound to mitochondria and measured 
by activity and N-domain HKI (□) remained bound to mitochondria and measured by His-tag 
antibodies and ELISA. 
 
 Release of HKI and N-domain HKI are indistinguishable by the kinetic ELISA assay (Fig. 
8). Evidently, the C-terminal half of HKI plays no significant role in the binding of HKI to the 
mitochondrion. Indeed, other evidence is consistent with this view. Polyclonal antibodies 
directed to the C-terminal half of HKI do not release HKI from mitochondria, whereas antibodies 
directed toward the N-terminal half of HKI cause release (63). Mutations to the Glc-6-P binding 
site at the N-terminal half greatly diminish release of HKI by Glc-6-P, but mutation to the Glc-6-
P site at the C-terminal half has little effect on release (44). The indistinguishable release of HKI 
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and N-domain-HKI but ATP and TNP-ADP is inconsistent with Mechanism I, which attributes 
release to nucleotide association with the C-terminal half of HKI. 
 A single-site binding model accounts for TNPADP association with HKI. That binding 
site is not part of the N-terminal half, as TNP-ADP binds weakly to N-domain HKI. Potent 
competitive inhibitor of TNP-ADP with respect to ATP is consistent with a high-affinity site at 
or near the active site of the C-terminal half. TNP-ADP does not bind to N-domain HKI and yet 
releases N-domain HKI from mitochondria, observations clearly inconsistent with Mechanism 
III. 
 Although it is relatively straightforward to exclude mechanisms of release, to actually 
prove the remaining mechanism (Mechanism IV) requires the accumulation of overwhelming 
experimental evidence. The approach here is to demonstrate correlations between nucleotide 
release of HKI from mitochondria and high affinity binding to human VDAC-1. In fact if 
Mechanism IV is correct, newly-discovered agents that bind to human VDAC-1 competitively 
with respect to TNP-ADP should also release HKI from mitochondria. The TNP-nucleotides 
(TNP-ATP, TNP-ADP, TNP-AMP, and TNP-CTP) bind to human VDAC-1 with high affinity 
(Table 1), and each is effective in the release of HKI from the mitochondrion (Table 3). The 
affinity of TNP-nucleotides to the mitochondrion, as measure by the release experiments (K3) 
and by fluorescence titrations (KL) are in reasonable agreement. Moreover, CDP does not 
displace TNP-ADP from human VDAC-1, and is not effective as a release agent (Figs. 6 and 10). 
These findings are consistent with Mechanism IV. If the target protein is not VDAC, then it must 
be another protein of equal abundance, able to bind TNP-nucleotides with similar high affinities, 
but not CDP. As VDAC is reportedly the most abundant protein in the outer leaflet, another 
protein with these attributes seems a remote possibility. 
 One should note, however, an apparent discrepancy within the body of data presented 
here. Firstly, 1/K3 for ATP release of HKI is ~5x10-5 M, whereas KA for ATP measured by 
fluorescence is ~5x10-4 M. The basis for this difference is unclear. Mg2+ is necessary for the 
association of HKI with mitochondria, and quite possibly ATP releases HKI not only through its 
interaction with VDAC, but also by chelation of Mg2+. ATP and ADP, however, are nearly equal 
in efficacy of HKI release. Moreover, release of HKI by TNP-nucleotides show no dependence 
on the number of phosphoryl groups, release efficacies and binding affinities being linked to the 
trinitrophenol functionality. Although TNP-ADP does not bind to the N-terminal half of HKI, 
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one cannot rule-out a release effect due to the binding of ATP (or ADP) to the N-terminal half. 
Mutations of residues at the ATP binding site of the N-terminal half, however, seem not to 
influence ATP release (Skaff, Honzatko, and Fromm, unpublished). ATP could bind to an 
additional site on VDAC which does not exclude the binding of TNP-ADP. An azido photo-
affinity label modifies VDAC at three positions that could map to distinct sites (50). 
  Although the focus here is on a mechanism of release, one can glean some basic 
understanding of the subunit stoichiometries in the HKI-VDAC-1 complex. Firstly, the ratio of 
HKI to VDAC must be at least one to one. If HKI is present at ratios less than unity with VDAC, 
then the observed reaction velocities in the absence of release agent are unachievable. A ratio of 
1:2 HKI to VDAC requires a doubling of the estimated number of VDAC molecules in the 
mitochondrion. HKI forms dimers (15, 48), and at least one report in the literature indicates a 
subunit tetramer of mitochondrion-bound hexokinase (64). An assumption of 4:1 HKI to VDAC 
for release data presented here decrease K1 by 20-fold (~107 M-1) and K3 by 4-fold, but the 
relative values of K3 remain unchanged. Hence, the affinity constants presented here are fairly 
insensitive to radical departures from the assumed 1:1 subunit ratio of the HKI-VDAC complex. 
Disruption of the hexokinase-mitochondrion association is the intention of potential anti-cancer 
drugs (66). Hexokinases I&II are often overexpressed in cancer cell lines, presumably to block 
pro-apoptotic signals which act through the release of cytochrome c from the mitochondrion. 
Remove hexokinase from the mitochondrion, and cancer cell succumb to apoptosis or have 
heightened sensitivity to existing treatments for cancer. Small molecules such as clotrimazole, 
bifonazole (67), 3-bromopyruvate (68) and methyl jasmonate (69) dissociate hexokinase from 
the mitochondrion. In most cases, the mechanism of release has not been determined, as has been 
here for the TNP-nucleotides and for Glc-6-P (44). VDAC evidently is a target for small 
molecules that release mitochondrion-bound hexokinase. As the trinitrophenol group seems 
critical to binding affinity and not the phosphoryl groups or nucleotide base, one has a reasonable 
expectation of finding a molecule of high specificity and within the parameters that define 
substances of potential pharmacological value. 
 Multimers of mitochondrion-bond HKI, to the extent that they form, must not involve 
interactions of C-terminal halves to be consistent with observations here. In fact, the simplest 
structural model consistent with release data is complex involving the N-terminal half of HKI 
with VDAC. Using the X-ray structure of mouse VDAC-1 (65), the N-terminal hydrophobic tail 
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of HKI most likely interacts with lipid and the external surface of the VDAC β-barrel. TNP-ADP, 
however, is highly anionic, having at pH 7.5 formal charges on the phosphoryl and nitro groups. 
The most probably binding site for this anion is somewhere at the inner surface of the VDAC 
barrel, which is lined with positively charged side chains. The model here is one of completion 
between TNP-ADP and HKI for VDAC, and leaves two possibilities: Either the binding of TNP-
ADP cause such significant conformational change in VDAC as to disrupt interactions involving 
the N-terminal resides of HKI or another set of surfaces residues of the N-terminal half of HKI 
are essential to the stability of the HKI-VDAC complex. 
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CHAPTER3: RESIDUES OF THE VOLTAGE DEPENDENT ANION CHANNEL 
(VDAC) CRITICAL FOR THE BINDING OF ATP 
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From the Roy J. Carver Department of Biochemistry, Biophysics and Molecular Biology 
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Running title: ATP binding to hVDAC-1 
Keywords: VDAC; mitochondria; ATP; TNP-ATP; fluorescence 
Background: Human VDAC-1 (hVDAC-1), the most abundant protein of the outer 
mitochondrial membrane, allows passage of ATP and ADP in/out of the mitochondrion.  
Results: The mutation of 15 lysine residues in the pore of hVDAC-1, generally reduced the 
binding affinity of ATP and TNP-AMP to hVDAC-1 by comparable levels ranging from 5- to 
20-fold; however,  K256M impacts the binding affinity of ATP and TNP-AMP by more than 
100-fold, whereas mutations of Lys61 and Lys113 have little, if any, effect. 
Conclusion: The side chains of most lysines in the pore contribute to the binding of ATP and 
TNP-AMP. The role of Lys256 seems by comparison critical to high-affinity binding, whereas 
lysines 61 and 113 seem unimportant. 
Significance: Lys256 is the first determinant of hVDAC-1linked to the high-affinity binding of 
ATP.  
 
ABSTRACT 
Hexokinase I (HKI) blocks the conducting state of the Voltage Dependent Anion Channel 
(VDAC) and blocks the formation of a permeability transition pore (PTP) associated with the 
release of cytochrome c from mitochondria during apoptosis. Metabolites of respiration (for 
instance, ATP and glucose 6-phosphate), as well as a fluorescent analog of ATP analog, TNP-
ATP, release HKI from the mitochondrion. Putatively, the site of ATP-binding in the release of 
HKI from mitochondria lies somewhere on VDAC, however, no firm evidence maps a high-
affinity binding of ATP to a specific site. Presented here is evidence for the binding of TNP-
AMP (Kd~1 μM) to a single site on isoform Type-1 of human VDAC (hereafter hVDAC-1). ATP 
displaces TNP-AMP from hVDAC-1 binding with high-affinity (Kd~10 μM). The individual 
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mutations of 15 lysine residues located in the pore of hVDAC-1 reduces ATP and TNP-AMP 
binding affinities comparably by 5- to 20-fold; however, K256M reduces ATP and TNP-AMP 
affinities by 100-fold whereas K51M and K113M have little or no effect. The results clearly 
establish a high-affinity binding site for ATP on hVDAC-1, and establish the side-chain of 
Lys256 as a critical determinant in ATP binding. 
INTRODUCTION 
VDAC regulates the energy balance of mitochondria and the entire cell by modulating 
the passage of metabolites between the organelle and cytoplasm (1-9). Silencing VDAC1 
expression inhibits cell growth through a reduction in energy production (10). Endogenous 
VDAC1 expression in transformed cells, suppressed by 70-90% using shRNA methodology, 
greatly impacts cell growth, reduced ATP synthesis by five-fold and decreased cellular levels of 
ATP and ADP by 50% (10). 
The pore diameter of a VDAC monomer is about 36 Å (measured from diametrically 
opposed Cα atoms), sufficiently large to pass most metabolites (such as ATP and ADP) but not 
large enough to pass proteins such as cytochrome c. The VDAC pore has many positively 
charged residues that should favor the entry of anions, and an N-terminal helix that partially 
blocks the pore (19, 20). Hence, the structural attributes of a mechanism to control the 
permeability of the outer mitochondrial membrane (OMM) is an integral part of VDAC. 
Regulation of OMM permeability, however, involves more than VDAC. Hexokinase 
Type I (HKI) and Hexokinase Type II (HKII) bind at high levels to the outer mitochondrial 
membrane, but not to vesicle or plasmid membranes. The abundance of bound HKI and/or HKII 
and the specificity of binding to the mitochondrion are consistent with an interaction between 
VDAC (the most abundant protein in the OMM) and HKI and/or HKII (11-16). In patch clamp 
studies, the addition of HKI abolishes ion conductance through VDAC (21). Moreover, HKII is 
overexpressed in cancer cells (by as much as 10-fold), presumably as an anti-apoptotic strategy 
(13). An overabundance of HKII covers the mitochondrion and blocks the formation of the 
permeability transition pore that leads to mitochondrial death. But if HKI and/or HKII remain 
bound to the OMM at all times, blocking anion conductance through VDAC, then how do 
adenine nucleotides exchange between the cytosol and mitochondrion? A mechanism must exist 
to modulate the interactions of HKI (and HKII) with the mitochondrial OMM, allowing at least 
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transitory passage of ATP and ADP.  One possible player in the transitory release of HKI (and 
perhaps HKII) from the mitochondrial membrane is glucose 6-phosphate (G6P), which binds 
with high affinity to the N-terminal half of HKI and releases mitochondrion-bound enzyme (22-
25). ATP (and ADP) may be also play a role, as both are effective in the release of HKI from the 
mitochondrion (Chapter 2, this thesis). 
Although several studies have shown ATP binding to VDAC (17, 18), crystallographic 
and NMR studies of VDAC did not reveal an ATP binding site (19, 20). Given that VDAC 
allows the passage of ATP/ADP to supply the energy needs of the cell and to regenerate ATP 
from ADP, the presence of a binding site for adenine nucleotides on VDAC is not an 
unreasonable expectation. 
Our approach here assumes the existence of an adenine nucleotide binding site 
somewhere on the interior surface of the VDAC pore, and that a subset of lysine side chains 
facilitate ATP/ADP binding and transport. The fluorescent analogs TNP-ATP, -ADP, -AMP and 
-CTP all bind to human VDAC-1 (hereafter hVDAC-1) with high affinity; however, ATP 
displaces TNP-AMP revealing a site with high affinity for ATP. Mutation of 15 lysine residues 
in the pore to methionine, reveals Lys256 as a significant determinant in the high-affinity 
binding of ATP. The affinity of ATP for this site (dissociation constant of ~10 μM) 
approximately matches the concentration of ATP necessary to release 50% of HKI from the 
mitochondrial membrane (Chapter 2, this thesis). 
 
EXPERIMENTAL PROCEDURES 
Materials— ATP, ADP, AMP, deoxyribonuclease (DNase I), protease cocktail inhibitor 
and phenylmethylsultonyl fluoride came from Sigma. Kanamycin sulfate and 2’3’-O-(2,4,6-
trinitrophenyl)-derivatives of ATP were came from Invitrogen. 2’3’-O-(2,4,6-trinitrophenyl)-
derivatives of ADP, AMP, CTP came from Jena Bioscience. Nickel-nitrilotriacetic acid-agarose 
(NiNTA) was from Novagen. Isopropyl-1-thio-β-D-galactopyranoside (IPTG) and 
Lauryldimethylamine-N-oxide (LADO) were from Anatrace. Oligonucleotides came from the 
Iowa IDT. Other materials came from Fisher Scientific. 
Cloning of Wild-type human VDAC-1 and mutant VDAC-1— A plasmid with the coding 
sequence of human VDAC-1 (hVDAC-1) was purchased from Open Biosystems. NdeI and SacI 
cut sites were created in the plasmid using the polymerase chain reaction (PCR) and NdeI primer 
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5'CGCGGCAGCCATATGATGGCTGTGCCACCCACG3' and SacI primer 
5'GGACTGGAATTTCAAGCA TCGAGCTCCGTCGACAAGC3'. The PCR product and vector 
pET-24a were digested by NdeI and SacI restriction enzymes. After separation on agarose gel, 
the DNA fragment for hVDAC-1 was ligated to pET-24a. Mutagenesis of conserved amino acids 
at the putative interior pore of hVDAC1 was acquired by PCR site-directed mutagenesis method. 
The interior lysine resides are located at residue numbers 28, 32, 61, 74, 96, 113, 115, 119, 174, 
197, 224, 236, 256, and 274. These resides were changed to methionine. The construction of 
each mutant employed designed primers as follows: for K28M, 5’- 
GCTATGGATTTGGCTTAATAATGCTTGATTTG-3’ (forward) and 5’- 
CAAATCAAGCATTATTAAGCCAAATCCATAGC-3’ (reverse); for K32M, 5’- 
TAATAAAGCTTGATTTGATGACAAAATCTGAG- 3’ (forward) and 5’- 
CTCAGATTTTGTCATCAAATCAAGCTTTATTA-3’ (reverse); for K61M, 5’- 
GGGCAGTCTGGAAACCATGTACAGATGGACTG-3’ (forward) and 5’- 
CAGTCCATCTGTACATGGTTTCCAGACTGCCC-3’ (reverse); for K74M, 5’- 
CGGCCTGACGTTTACAGAGATGTGGAATACCG-3’ (forward) and 5’- 
CGGTATTCCACATCTCTGTAAACGTCAGGCCG-3’ (reverse); for K96M, 5’- 
CAGCTTGCACGTGGACTGATGCTGACCTTCGA-3’ (forward) and 5’- 
TCGAAGGTCAGCATCAGTCCACGTGCAAGCTG-3’ (reverse); for K113M, 5’- 
CTGGGAAAAAAAATGCTATGATCAAGACAGGG-3’ (forward) and 5’- 
CCCTGTCTTGATCATAGCATTTTTTTTCCCAG-3’ (reverse); for K115M, 5’- 
GCTAAAATCATGACAGGGTACAAGCGGGAGCA-3’ (forward) and 5’- 
TGCTCCCGCTTGTACCCTGTCATGATTTTAGC-3’ (reverse); for K119M, 5’- 
CAAGACAGGGTACATGCGGGAGCACATTAACC-3’ (forward) and 5’- 
GGTTAATGTGCTCCCGCATGTACCCTGTCTTG-3’ (reverse); for K174M, 5’- 
GCAGTTGGCTACATGACTGATGAATTCCAGCT -3’ (forward) and 5’- 
AGCTGGAATTCATCAGTCATGTAGCCAACTGC -3’ (reverse); for K197M, 5’- 
GGCGGCTCCATTTACCAGATGGTGAACAAGAA-3’ (forward) and 5’- 
TTCTTGTTCACCATCTGGTAAATGGAGCCGCC-3’ (reverse); for K224M, 5’- 
GCGCTTCGGAATAGCAGCCATGTATCAGATTG-3’ (forward) and 5’- 
CAATCTGATACATGGCTGCTATTCCGAAGCGC-3’ (reverse); for K236M, 5’- 
CTGCTTCTCGGCTATGGTGAACAACTCCAGCC-3’ (forward) and 5’- 
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GGCTGGAGTTGTTCACCATAGCCGAGAAGCAG-3’ (reverse); for K256M, 5’- 
CTAAAGCCAGGTATTATGCTGACACTGTCAGC-3’ (forward) and 5’- 
GCTGACAGTGTCAGCATAATACCTGGCTTTAG-3’ (reverse); for K274M, 5’- 
CAATGCTGGTGGCCACATGCTTGGTCTAGGAC-3’ (forward) and 5’- 
GTCCTAGACCAAGCATGTGGCCACCAGCATTG-3’ (reverse). The N-terminal helix of 
hVDAC-1 was truncated by restriction enzyme digestion and ligation method introducing an 
additional NdeI cut site between residues 20 and 21. This site was introduced by PCR using 5’- 
TTCACCAAGCATATGGGCTATGGATTTGGCTTA-3’ (forward) and 5’- 
TAAGCCAAATCCATAGCCCATATGCTTGGTGAA-3’ (reverse). All the constructs were 
confirmed by the DNA sequencing facility at Iowa State University. 
Expression and purification of hVDAC-1— hVDAC-1 purification and folding follows 
protocols in the literature (18, 26) with modifications. hVDAC-1 containing plasmid was 
transformed into E. coli strain BL21 (DE3). Cells were grown in LB media at 37 °C, kanamycin 
was added to a final concentration of (30 μg/mL). Growth was monitored by absorbance at 
wavelength 600 nm. At A600 of 0.9, the temperature was reduced to16 °C and IPTG was added 
to a final concentration of 0.3 mM. Cells were collected after 16-20 hours of induction and 
suspended in lysis buffer (30 mM Tris-HCl, pH8.0, 150 mM NaCl, 1mM EDTA, and 1mM 
DTT). DNase (50 μg/mL), leupeptin (5 μg /mL), and PMSF (1 mM) were all added to the 
solution. Cells were lysed by sonication. Inclusion bodies were pelleted at 16,0000 rpm for 1 hr. 
Pelleted inclusion bodies were subjected to the following procedures three times: separation from 
the supernatant fraction, suspension in wash buffer (30 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 
mM EDTA, 1 mM DTT) and centrifugation at 15,000 rpm for 30 minutes. Inclusion bodies were 
suspended in 30 mL of wash buffer plus 1% Triton X-100, incubated for 45 minutes at 37 °C, 
and then suspended and washed twice with wash buffer. Washed inclusion bodies were 
solubilized in 10 mL dissolving buffer (6 M guanidine hydrochloride, 10 mM DTT, 0.1 mM 
EDTA, 100 mM Tris-HCl, pH8.0). Inclusion bodies dissolved completely in 12 hr. at 4 °C. 
About 20 mL of unfolded solubilized hVDAC-1 were added dropwise into 300 mL of refolding 
buffer (0.1 mM EDTA, 1 mM DTT, 100 mM Tris-HCl, pH8.0, 2% LDAO) at 4 °C to reduce 
concentration of guanidine hydrochloride around 0.4~0.8 M. Refolded protein was concentrated 
and dialyzed against 50 mM Tris-HCl. pH 7.5, 0.1% LDAO buffer for 24 hrs. at 4 °C. Solution 
was loaded onto a nickel-nitrilo triacetic acid (Ni2+-NTA) column. The column was washed with 
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buffers containing 50 mM Tris-HCl, pH7.5, 300 mM NaCl, 0.1% LDAO and 5 mM imidazole 
and then 50 mM imidazole. Finally, hVDAC-1 was eluted with the same buffer containing 300 
mM imidazole. 
Conformational analysis of VDAC-1 mutants—Far-UV circular dichroism spectroscopy 
was used to verify similar folds for wild-type and mutant hVDAC-1. Spectra were recoded from 
260-190 nm with 1 nm increments. Secondary structure was estimated from the wild-type 
spectrum by DichroWeb, provided by Prof. B. A. Wallace at the University of London. Spectra 
were collected for mutants to confirm unperturbed secondary structure relative to the wild-type 
protein. 
hVDAC-1 fluorescence experiments— Purified hVDAC-1 were dialyzed against 2 mM 
glucose and 50 mM Tris-HCl, pH 7.5. Fluorescence measurements were made at room 
temperature using a 1-cm2 quartz cuvette on a SLM Amico 8000 fluorimeter. For TNP-
nucleotides the excitation wavelength was 409 nm, and emission scans were from 450 to 600 nm. 
An excitation wavelength of 295 nm was chosen to avoid exciting tyrosyl side chains for 
tryptophan fluorescence experiments. Emission spectra were recoded from 310 to 400 nm. 
Fluorescence scans (a total of three for each datum) were performed after additions of small 
volumes of TNP-nucleotide to 2 mL of 2.5 μM hVDAC-1. TNP-nucleotide displacement was 
accomplished by the addition of the alternative nucleotide to 1 mL solution of 2.5 μM hVDAC-1 
and 1-μM TNP-nucleotide. For each kind of experiment, the total concentration of added titrant 
did not exceed 5% of the initial volume of solution, and the total concentration of titrant was 
corrected for volume changes. The analysis of fluorescence data followed the approach of Fallar 
(59), modified as described in the Results section, using GraFit to perform nonlinear least 
squares fitting. 
RESULTS 
Validation of mutant hVDAC-1 — Circular dichroism spectra where taken of wild-type 
(Fig.1) and 14 methionine mutants. The wild type spectrum indicated 16% of all residues as α-
helix and 81% β-strand (Table 1). These numbers compare favorably to those determined from 
the crystal structure of VDAC. The spectra of all methionine mutants matched that of wild-type 
hVDAC-1. 
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TABLE 1. Wild-type hVDAC-1 analysis by Dichroweb (Lee Whitmore and B. A. Wallace).  
  Helix1 Helix2 Strand1 Strand2 Turns Unordered Total 
wt-
hVDAC-1 0.000 0.157 0.117 0.694 0.008 0.024 1.000 
 
 
FIGURE 1. CD spectrum of wild type hVDAC-1. 
TNP-nucleotides binding to wild-type hVDAC-1— The experiment employed the same 
method as previously described (Chapter 2, this thesis). The observed fluorescence comes from 
free TNP-nucleotides, TNP-nucleotides bound to hVDAC-1, and hVDAC-1 itself: 𝐹𝐹obs = 𝐹𝐹free +
𝐹𝐹bound + 𝐹𝐹scatter. The term Fscatter accounts for all intensity not directly from the fluorophore TNP-
ATP. The principle contribution to Fscatter is the protein, and as the concentration of protein is 
fixed and has no fluorophore subject to excitation at 409 nm, Fscatter has a small constant value. 
Ffree = a + b[L] - c[L]2, where a, b, and c are determined by a fit of fluorescence versus free 
concentrations of fluorescent ligand [L] in the absence of protein under buffer conditions 
identical to those used in the titration of hVDAC-1. Fbound = γb(Lo – [L]), where γ is a 
fluorescence enhancement factor of the bound relative to the free state of the fluorescent ligand 
and Lo is the total concentrations of fluorescent ligand. The value for [L] above goes into the 
relationship for Fobs: Fobs = a + b[L] – c[L]2 + γb(Lo – [L]) + Fscatter (Eqn. 1). The derivation of 
this equation assumes one site per protein molecule, but it also has a simple solution if there are 
N identical, independent sites per protein molecule (Chapter 2, this thesis). Mass conservation 
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relations for total protein Po = [P] + [PL] and total ligand Lo = [L] + [PL], when combined 
results in a quadratic equation in free ligand concentration [L], the positive root of which 
represents [L] in terms of Lo, Po and an equilibrium dissociation constant KL = [P]*[L] / [PL].  
Substitution of the positive root into Eqn. 1 gives Fobs as a function of Fscatter, Po, Lo and 
adjustable parameters KL and γ.  GraFit software optimizes the fit of the observed fluorescence at 
fixed Po and varying Lo by adjusting parameters KL and γ. Analog TNP-ATP binds to hVDAC-1 
with high affinity (KL = 0.5 ± 0.2 μM, γ = 16.4 ± 0.9, Fscatter = 0.5 ± 0.08) (Fig. 2). Analogs TNP-
ADP, TNP-AMP and TNP-CTP bind to hVDAC-1 similarly to TNP-ATP (Table 2).  Picric acid, 
the TNP fluorophore exhibits no binding. 
Although the single-site model generally accounts for observed fluorescence, the 
observed fluorescence for the TNP-ATP titration departs systematically from the fitted curve for 
a single-site model. One possible explanation for the departure is the presence of an additional 
binding site for TNP-ATP. Other analytical models were attempted (two independent binding 
sites, two populations of VDAC); however, the improvement of the goodness of fit did not 
justify the increase in the number of adjustable parameters of more complex models. Results in 
the next section, however, are consistent with multiple binding sites for TNP-ATP. On the other 
hand, a single-site model accounts for the observed fluorescence from the titration of hVDAC-1 
by TNP-AMP. 
 
TABLE2. TNP-nucleotides and picric acid binding to wild-type hVDAC-1. Parameters are from 
a single binding site model. KL, γ and Fscatter are constants for the dissociation of substrates from 
hVDAC-1. Fluorescence was measured at varying total concentrations of ligands in 2 mM 
glucose and 50 mM Tris-HCl, pH 7.5. Standard deviations in the last significant digits are given 
in parentheses. 
 
Ligand KL(µM) γ Fscatter 
TNP-ATP 0.5 (2) 16.4 (9) 0.45 (8) 
TNP-ADP 1.2 (2) 21.4 (8) 0.06 (2) 
TNP-AMP 2.0 (1) 20.4 (3) 0.13 (2) 
TNP-CTP 0.7 (1) 11.2 (3) 0.22 (2) 
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FIGURE 2. Titration of wild-type hVDAC-1 with fluorescent ligands. Plots represent 
fluorescence at varying total concentrations of ligand in 2 mM glucose and 50 mM Tris-HCl, pH 
7.5, with 2.0 μM wild-type hVDAC-1 and 1-μM TNP-nucleotide. TNP-ATP (●), TNP-ADP 
(○), TNP-AMP (●), TNP-CTP (▲) and picric acid (□). 
 
Displacement of TNP-nucleotides by ATP— As before, the observed fluorescence is 
given by Eqn. 1; however, Fobs must be cast as a function of total ligand concentration Ao used in 
displacement titration of the bound fluorophore. Mass conservation and equilibrium relationships 
are as follows: Lo = [L] + [PL], Ao = [A] + [PA], Po = [P] + [PA] + [PL], KL = [P]*[L] / [PL], 
and KA = [P]*[A] / [PA].  The equilibrium relationships and mass conservation relations for Lo 
and Ao can be used to rewrite mass conservation relationship for protein as Po = [P] + [P]*Ao / 
(KA + [P]) + [P]*Lo / (KL + [P]). Assuming [P]<<KA one obtains a quadratic in [P], the positive 
root of which can be substituted into Eqn.1 to give Fobs as a function of Fscatter, Po, Ao, Lo, KA, KL 
and γ. Using values from Table 1 for KL, and experimentally determined values for Po, Ao and Lo, 
curve fitting employed Fscatter, KA and γ. 
ATP released each of the TNP-nucleotides (Fig. 3) with the following values for KA: for 
TNP-ATP, KA = 1100 ± 300 µM; for TNP-ADP, KA = 550 ± 40 µM; for TNP-AMP, KA = 14 ± 1 
µM and for TNP-CTP, KA = 210 ± 20 µM. If each TNP-nucleotide binds to the same site on 
hVDAC-1, then KA (representing the dissociation constant of ATP from its binding site on 
hVDAC-1) should be the same. Clearly, this is not the case. ATP interacts relatively weakly 
(<KA>~600 μM) at sites occupied by TNP-ATP, TNP-ADP and TNP-CTP. In contrast, ATP 
binds strongly (KA~10 μM) to the site occupied by TNP-AMP. Given the good agreement 
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between the single-site model and titration binding curve for TNP-AMP (Fig. 1), and given the 
likelihood of a high-affinity binding site for ATP by its displacement of TNP-AMP, further 
analysis of mutant forms of hVDAC-1 employs TNP-AMP as a fluorescence probe. 
 
 
FIGURE 3. ATP titrations of wild-type hVDAC-1 ligated with TNP-nucleotides. Plot represents 
the fluorescence at varying total concentrations of ATP in 2 mM glucose and 50 mM Tris-HCl, 
pH 7.5, with 2.0 μM wild-type hVDAC-1 and 1-μM TNP-nucleotide. TNP-ATP (●), TNP-ADP 
(○), TNP-AMP (●), TNP-CTP (▲) 
 
TNP-AMP binding to mutants of hVDAC-1— ATP displacement of bound TNP-AMP 
probed the effects of mutations on ATP binding to hVDAC-1. This approach requires a 
determination of binding affinity of TNP-AMP to each mutant form of hVDAC-1 first in order to 
determine the binding affinity of ATP. Fluorescence titrations and subsequent fitting followed 
the procedure above for wild-type hVDAC-1. The results are in Table 3, and the KL for TNP-
AMP relative to that of wild-type hVDAC-1 appears in Fig. 4. N-terminal helix-truncated 
hVDAC-1 was also tested for TNP-AMP binding affinity exhibiting a 10-fold reduction relative 
to wild-type hVDAC-1 (KL = 6 ± 1 μM, γ = 4.4 ± 0.4, Fscatter = 0.06 ± 0.01). 
TNP-AMP displacements by ATP— Displacement of TNP-AMP by ATP measures the 
binding affinity of the high-affinity site for ATP. The displacement titration and analysis of 
observed fluorescence follows the protocol above in previous displacement titrations using ATP. 
Results are in Table 4. ATP-displacement of TNP-AMP from N-terminal helix-truncated 
hVDAC-1 produced a KA = 430 ± 3 μM with γ = 4.0 ± 0.1 and Fscatter = 0.10 ± 0.01). 
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TABLE 3. TNP-AMP binding to different constructs of hVDAC-1. Parameters KL, γ and Fscatter 
are from a single-site binding model, where KL is the dissociation constant for TNP-AMP from 
its protein-ligand complex, γ is the fluorescence enhancement factor and Fscatter represents 
background radiation. Fluorescence was measured at varying total concentrations of TNP-AMP 
in 2 mM glucose and 50 mM Tris-HCl, pH 7.5. Standard deviation in the last significant digit is 
given in parentheses. 
  KL (µM) γ Fscatter 
WT 0.5 ( 1) 5.1 (1) 0.09 (1) 
K28M 3.6 ( 6) 5.9 (3) 0.07 (1) 
K32M 2.5 ( 4) 3.0 (1) 0.05 (5) 
K61M 0.8 ( 2) 3.3 (1) 0.06 (9) 
K74M 3.0 ( 1) 3.9 (3) 0.07 (1) 
K96M 8.0 ( 1) 8.2 (5) 0.09 (8) 
K113M 0.3 ( 1) 4.0 (1) 0.08 (1) 
K115M 3.8 ( 6) 5.2 (3) 0.06 (9) 
K119M 1.9 ( 4) 4.3 (2) 0.08 (1) 
K174M 2.9 ( 5) 4.4 (2) 0.08 (9) 
K197M 3.0 ( 1) 6.2 (7) 0.04 (3) 
K224M 4.1 ( 9) 4.8 (3) 0.07 (1) 
K236M 2.9 ( 5) 4.4 (2) 0.08 (9) 
K256M 40 (30) 10 (6) 0.06 (5) 
K274M 7.0 ( 2) 4.4 (7) 0.05 (1) 
 
 
FIGURE 4. Change in binding affinity of TNP-AMP for mutant relative to wild-type hVDAC-1. 
The height of each bar indicates the ratio of KL-mutant/KL-wildtype.  K61M and K113M had 
essentially no effect on TNP-AMP binding, whereas K256M weakened binding by 80-fold. Error 
bars are one sigma-(A/B) = SQRT[(1/B)2*(sigma-A)2 + (A/B2)2*(sigma-B)2], where A and B are 
values for KL-mutant and KL-wildtype, respectively. Uncertainty in the parameters for K256M is 
high simply because the KL is far above the limiting concentration of 14 μM for TNP-AMP 
titrations. 
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TABLE 4. TNP-AMP displacement by ATP for constructs of hVDAC-1. Parameters are from a 
single binding-site model. KA, γ and Fscatter are constants for the displacement of TNP-AMP by 
ATP from hVDAC-1. Fluorescence was measured at varying total concentrations of ATP in 2 
mM glucose and 50 mM Tris-HCl, pH 7.5, with 2.0 μM wild-type hVDAC-1 and 1-μM TNP-
AMP. Standard deviation in the last significant digits is given in parentheses. 
Construct KA [µM] γ Fscatter 
WT 14 (    1) 9.0 (2) 0.23 (2) 
K28M 210 (  20) 6.7 (2) 0.19 (2) 
K32M 180 (  20) 3.8 (1) 0.10 (1) 
K61M 35 (    4) 5.5 (2) 0.19 (1) 
K74M 480 (  50) 7.5 (2) 0.18 (2) 
K96M 340 (  60) 4.9 (2) 0.10 (3) 
K113M 36 (    7) 5.3 (2) 0.14 (3) 
K115M 500 (  60) 5.4 (1) 0.16 (2) 
K119M 160 (  30) 4.7 (2) 0.15 (2) 
K174M 300 (  40) 8.1 (2) 0.25 (3) 
K197M 290 (  30) 5.6 (1) 0.22 (1) 
K224M 160 (  20) 4.9 (1) 0.25 (1) 
K236M 140 (  20) 6.6 (2) 0.33 (2) 
K256M 900 (100) 7.4 (3) 0.21 (1) 
K274M 660 (  70) 6.4 (2) 0.27 (1) 
 
 
FIGURE 5. Change in binding affinity of ATP for mutant relative to wild-type hVDAC-1. The 
height of each bar indicates the ratio of KA-mutant/KA-wildtype.  K61M and K113M had 
essentially no effect on ATP binding (consistent with the absence of an effect on TNP-AMP 
binding affinity), whereas K256M weakened binding by at more than 10-fold.  Error bars are one 
sigma-(A/B) = SQRT[(1/B)2*(sigma-A)2 + (A/B2)2*(sigma-B)2], where A and B are values for 
KA-mutant and KA-wildtype, respectively. 
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Effect of TNP-ATP on tryptophan fluorescence of wild-type of hVDAC-1 and tryptophan 
mutants of hVDAC-1— The following line of investigation probed whether TNP-nucleotides 
displace the N-terminal helix of hVDAC-1 from the barrel, and provided independent 
confirmation of the measured value of KL for the binding of TNP-ATP. Tryptophan mutations of 
Tyr7 and Phe18, both part of the N-terminal helix of hVDAC-1, introduced fluorophores at two 
positions. Using an excitation wavelength of 295 nm, tryptophan fluorescence could be 
monitored in response to the titration of TNP-ATP. Titration curves were analyzed by following 
equation: ∆𝐹𝐹
𝐹𝐹0
=  (∆𝐹𝐹𝑚𝑚𝑚𝑚𝑚𝑚/𝐹𝐹0)𝐿𝐿𝑛𝑛
𝐾𝐾𝐿𝐿+ 𝐿𝐿𝑛𝑛  (Eqn. 2) (Biochem 39, 36, 11100-11106). ∆F is the change in 
fluorescence due to the presence of ligand L, Fo is the fluorescence in the absence of ligand, Fmax 
is the fluorescence at the highest concentration of ligand, KL the dissociation constant and n the 
Hill coefficient. Changes in tryptophan fluorescence in response to the binding of TNP-ATP (Fig. 
6) established a 2-fold difference in the determination of KL by the two methods (Table 5).  
Moreover, the increase in fluorescence as TNP-ATP increases indicates a tighter binding of the 
N-terminal helix a TNP-ATP increases.  TNP-ATP did not exhibit fluorescence at an excitation 
wavelength of 295 nm. 
 
FIGURE 6. TNP-ATP titration of the tryptophan mutants. Plot represents the fluorescence at 
varying total concentrations of TNP-ATP in 2 mM glucose and 50 mM Tris-HCl, pH 7.5, with 
mutant hVDAC-1 2.0 μM. Y7W (○), F18W (●) 
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TABLE 5. Comparison of dissociation constant determined by TNP-ATP excitation (409 nm) 
and tryptophan excitation (295 nm). Parameters are from each fluorescence analysis model as 
describe in the text. Fluorescence was measured at varying total concentrations of TNP-ATP in 2 
mM glucose and 50 mM Tris-HCl, pH 7.5. Standard deviations in the last significant digit are in 
parentheses. 
Excitation 
wavelength (nm)   KL (µM) γ Fscatter n 
409 
WT 0.5 (2) 16.4 (9) 0.5 (1) NA 
Y7W 0.6 (6) 6.8 (2) 0.16 (2) NA 
F18W 0.7 (6) 6.7 (1) 0.10 (2) NA 
295 Y7W 0.9 (1) NA NA 0.8 (1) F18W 1.5 (1) NA NA  1.0 (1) 
 
DISCUSSION 
TNP-nucleotides bind with high affinity to hVDAC-1. The TNP-ATP dissociation 
constant is twofold lower than that of TNP-ADP, and four-fold lower than that of TNP-AMP, but 
roughly the same as that for TNP-CTP. The data indicate a weak dependence on the number of 
phosphoryl groups and no dependence on the type of nucleotide base. The TNP moiety is 
essentially picric acid, but picric acid alone does not bind with high affinity to hVDAC-1. 
Binding seems determined by the phosphoryl groups, but may be limited primarily to the α-
phosphoryl group, or may preclude interactions involving multiple phosphoryl groups. These 
observations suggest that anions present in buffers could have a significant impact on apparent 
binding affinities of nucleotides. Work here employed Tris-HCl, making Cl– the dominant anion 
in the system at a concentration of approximately 25 mM. 
TNP-ATP exhibited a titration curve not consistent with a single fluorophore binding to 
hVDAC-1. Fluorescence increased smoothly and began to plateau after the total concentration of 
TNP-ATP reached 2 μM.  Higher concentrations of TNP-ATP resulted in a reproducible rise in 
fluorescence, not linked to any discernable aspect in the delivery of titrant (such as changing the 
volume settings on the pipette). The behavior is indicative of the binding of a second molecule of 
TNP-ATP; however, fitting such data proved problematic because of the introduction of a second 
KL and γ to account for another binding interaction. Multiple binding of ATP analogs to VDAC 
have been observed previously (17). Two molecules of benzoyl-benzoyl-ATP bind to VDAC 
indicating high- and low-affinity sites, and resulting in multiple sites of labeling after 
photoexcitation. 
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The titration curve using TNP-AMP exhibited no evidence of anything more complicated 
than the binding of a single fluorophore. Hence, with reasonable confidence ATP displacement 
of TNP-AMP reflects a simple exchange of molecule of ATP for one molecule of TNP-AMP, 
consistent with the model (mutually exclusive binding of TNP-AMP and ATP) used for the 
analysis of data. The KA value (1100 μM) for ATP in its displacement of TNP-ATP indicates a 
low affinity interaction, whereas the KA value (14 μM) for ATP in its displacement of TNP-AMP 
indicates a high affinity site of interaction. 
The binding of TNP-AMP and displacement by ATP through interactions that involve 
primarily a phosphoryl group implicates one or more positively charged lysine residues in the 
pore of hVDAC-1. There are 15 candidates, and most seem involved, perhaps through indirect 
electrostatic interactions, but certainly lysines 61 and 113 (co-localized on one side of the barrel) 
are not involved, whereas Lys256 and Lys274 (co-localized on the opposite side of the barrel) 
are involved significantly (Fig. 7). ATP and TNP-AMP have common patterns of interaction. 
 
 
FIGURE 7. Mapping pore lysine residues to VDAC structure (PDB 3EMN). The color of lysine 
residues represents the effect of the mutation relative to K256M, calculated by (Kmutant–
Kwildtype)/(KK256M–Kwildtype), where K represents KL for TNP-AMP or KA for ATP. The effects of 
mutations range from 0 to 1 relative to K256M, with 1=100% red and 0=0% red (i.e., white). 
Panels A and B are effects of mutation on the binding affinities of TNP-AMP and ATP, 
respectively. 
A B 
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In other words, mutations have similar impacts on ATP (three phosphoryl groups and no TNP 
moiety) and TNP-AMP (one phosphoryl group and one TNP group). Structurally, these 
molecules differ significantly, and the active site of an enzyme should have little difficulty in 
distinguishing ATP from TNP-AMP. The VDAC pore, however, is not an active site, but a 
channel for the passage of anions. TNP-AMP and ATP have nearly the same formal charge (–4) 
at pH 7.5, and it may be that Lys256 and Lys274 form hydrogen bonds with the α-phosphoryl 
group of each ligand with other lysine residues interacting electrostatically over distances beyond 
3.5 Å. 
The passage of an anion through hVDAC-1 must overcome the N-terminal helix which 
resides in the pore. The truncation of the N-terminal helix substantially decreases the binding 
affinities of TNP-AMP and ATP (Tables 4 & 5). The involvement of the N-terminal helix in 
interacting with ATP and TNP-AMP is evident from the substitution of Phe18 or Tyr7 with 
tryptophan. Tryptophan fluorescence increases in response to the titration of TNP-ATP, 
indicating diminished access of the tryptophan sidechains at positions 7 and 18 to solvent, which 
would be consistent with nucleotide binding within the pore without the displacement of the 
helix. Hence, the ATP and TNP-AMP complexes here represent anion binding to a close state of 
hVDAC-1 (Fig. 8). 
How does hVDAC-1 pass ATP if the high-affinity state for ATP is associated with a 
closed pore? Conceivably, under a membrane potential difference of a respiring mitochondrion, 
this closed state may open. Another mechanism may exist that involves a second, low-affinity 
binding site for ATP (Fig. 8). The ATP molecule stationed at the high-affinity site may indeed 
stabilize a close hVDAC-1. The binding of a second molecule of ATP, which would occur only 
in the presence of a high mitochondrial concentration of ATP, would then weaken the high-
affinity interaction (the second molecule of ATP antagonizes the binding of first molecule) 
which in turn destabilizes the closed pore (gate opens in response to the second binding event). A 
mechanism of this kind opens the pore only when a molecule of ATP is in position to leave. 
Work of Maskey (MS thesis) favors the binding of the N-terminal helix of HKI to the 
outside of the hVDAC-1 barrel, placing the N-terminal half over the pore of hVDAC-1. The 
displacement of the N-terminal helix of hVDAC-1 could force reorientation of HKI so that its 
high-affinity binding site for ADP at the N-terminal half faces the pore opening.  As ATP exits 
the open pore, a molecule of ADP bound to HKI is positioned to enter the pore.  Are any of these 
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ideas subject to experimental verification?  Perhaps through the introduction of CRISPR/CAS9 
methods mutant forms of hVDAC-1 (for instance, K256M) and/or HKI (elimination of the N-
terminal ADP site) could determine whether specific binding sites have significant impact on cell 
growth and ATP levels. 
 
FIGURE 8.  Possible mechanism of ATP movement through hVDAC-1. The N-terminal helix 
(parallelogram) resides in the interior of closed hVDAC-1 (left). ATP molecules (circles) bind to 
the hVDAC-1 interior causing a significant change in net electrostatic charge, which then 
triggers helix movement (middle). N-terminal helix opens to the cytosolic side of the outer 
mitochondrial membrane when ATP molecules fill the low affinity biding site (or sites) (right). 
OMM represents outer mitochondrial membrane. IM means the inner membrane space of the 
mitochondrion. 
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CHAPTER 4: CONFOCAL MICROSCOPIC VISUALIZATION OF THE 
INTERACTION BETWEEN FLUORESCENCE-LABELED CONSTRUCTS OF  
HEXOKINASE TYPE I (HKI) WITH VOLTAGE DEPENDENT ANION CHANNELS 
(VDAC) LOCALLIZED TO THE MEMBRANE OF GIANT UNILAMELLAR 
VESICLES (GUV) 
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Running title: Interaction of HKI Constructs with VDAC 
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Background: Evidence suggests the direct interaction of HKI with VDAC of the outer 
mitochondrial membrane.  
Results: VDAC embedded in the outer membrane of artificial vesicles binds and releases 
fluorescence-tagged constructs of HKI comparably to intact mitochondria. 
Conclusion: The presence of VDAC alone is sufficient to bind constructs of HKI to membrane. 
The presence of the first 26-resdues of the N-terminal tail of HKI is sufficient to localize 
constructs of HKI to membranes containing VDAC. 
Significance: Data here represent the first evidence for a direct interaction between VDAC and 
HKI. 
 
ABSTRACT 
 Human hexokinases Type I and Type II (HKI & HKII) bind the outer mitochondrial 
membrane, being among the first enzymes of the cytosol to have access to ATP, while 
desensitizing mitochondria toward pro-apoptotic signals. Several lines of evidence show 
correlations between the status of the voltage dependent anion channel (VDAC) and the binding 
of HKI or HKII to the outer mitochondrial membrane, but no investigation has provided 
evidence for a direct interaction between VDAC and either HKI or HKII. Giant unilamellar 
vesicles (GUVs) of lipid composition comparable to that of the outer mitochondrial membrane 
do not bind fluorescent constructs of HKI as visualized by confocal microscopy; however, such 
vesicles bind HKI constructs when recombinant VDAC is embedded in the membrane. N-
terminal half HKI tagged with either green fluorescent protein (GFP) or FlAsH-modified 
tetracysteine is released from vesicles by glucose 6-phosphate (G6P) or ATP, comparable to the 
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release of HKI from pig liver mitochondria. A construct composed of the first 26-residues of 
HKI tagged with GFP or FlAsH-modified tetracysteine binds to VDAC-embedded GUVs as well.  
ATP releases such constructs but G6P does not, consistent with different mechanisms of action 
for each ligand. The observations reported here can be reconciled only by a direct interaction of 
HKI with VDAC. 
INTRODUCTION 
Apoptosis is a naturally occurring process by which a cell is programed to self-destruct. 
Apoptosis is based on genetic information that is an indispensable part of the development and 
function of an organism. There are at least two broad pathways of apoptosis known as an 
"extrinsic" and "intrinsic". The extrinsic pathway begins when conditions in the extracellular 
environment determine that a cell must die. Intrinsic apoptosis begins when an injury (or 
malfunction) occurs within the cell. Mitochondrially-linked apoptosis is the best known intrinsic 
apoptosis pathway (1, 2). Substantial evidence suggests VDAC as a critical player in the release 
of apoptogenic proteins from mammalian mitochondria (3-8). Cytochrome c release, interactions 
between the pro-apoptotic proteins and VDAC, and the initiation of cell death are impeded by 
anti-VDAC antibodies, indicating the central importance of VDAC in the intrinsic apoptosis 
pathway (9-11). 
The other evidence for VDAC involvement is demonstrated by over-expression and 
down-expression of VDAC in vivo. Over-expression of human, murine, yeast, Paralichthys 
olivaceus, and rive VDAC was found to induce apoptotic cell death regardless of cell type (12-
16). On the other hand, siRNA-mediated down-expression of VDAC prevented cell death 
induced by pro-apoptotic proteins (7). Hexokinase Type-I (HKI) and Type-II (HKII) antagonize 
the formation of apoptotic channels. Some have gone so far as to label hexokinase as “guardian 
of the mitochondria” because of its anti-apoptotic properties (17). Hexokinase co-localizes 
differentially with human VDAC-1, -2 and -3 (18). HKI binding to mitochondria inhibits ATP 
flux through VDAC-1 (19). Over expression of N-terminally truncated VDAC-1 did not induce 
cells to release cytochrome c and the cells were resistant to apoptosis (6). The N-terminal peptide 
of VDAC-1 and other VDAC-1 based peptides bind to immobilized HKI. These peptides 
prevented protection of cells by HKI (20). 
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Specific residues in VDAC are likely to be important for the interaction between VDAC 
and HKI. Chemical modification of Glu73 eliminated the binding of HKI to mitochondria (16). 
Mutating Glu73 of VDAC abolished anti-apoptotic effects due to the overexpression of HKI in 
different cancer cells (21). Adding HKI to VDAC1 reconstituted in lipid membrane reduced 
channel conductance (22). The addition of HKI to Glu73Gln VDAC did not terminate ion 
conductance, indicating the failure to form a HKI-mutant VDAC complex (21). A number of 
small and physiological important ligands dissociate HKI from the mitochondrial outer 
membrane. For instance, a photoactive ATP analog, Bz-ATP (benzoyl-benzoyl-ATP), can bind 
to sites on VDAC-1 with low and high binding affinities (23). Mutating residues in predicted 
nucleotide-binding site in VDAC-1 reduced ATP cellular levels and caused sluggish cell growth 
(24). 
Giant unilamellar vesicles (GUVs) could function as an artificial substitute for the outer 
membrane of the mitochondrion, offering the prospect of a “simplified” outer mitochondrial 
membrane with known constituents. Stability, flexibility, and viscosity of the GUV membrane 
can be adjusted as necessary in order to capture integral membrane proteins. The challenge in 
developing a “functional” GUV comes in the capture of VDAC molecules with orientation and 
conformation that approximates VDAC molecules in the outer membrane of the mitochondrion. 
Based on the previous study (Chapters 2&3, this thesis) TNP-ATP binds with high affinity to 
VDAC. In this study, we exhibit the capture of VDAC in the membrane of GUVs. The VDAC-
embedded GUVs bind fluorescent constructs of HKI, consistent with HKI binding to the 
mitochondrion. Moreover, glucose 6-phosphate (G6P) and ATP release constructs of HKI 
comparably to the release of HKI from mitochondria. Work here represents the first evidence for 
a direct interaction between HKI and VDAC, showing VDAC allow is sufficient and necessary 
to localized HKI to a membrane. 
 
EXPERIMENTAL PROCEDURES 
Materials— ATP, deoxyribonuclease (DNase I), protease cocktail inhibitor and 
phenylmethylsultonyl fluoride came from Sigma. Kanamycin sulfate was from Invitrogen. 
Nickel-nitrilotriacetic acid-agarose (NiNTA) was from Novagen. Isopropyl-1-thio-β-D-
galactopyranoside (IPTG) and Lauryldimethylamine-N-oxide (LADO) came from Anatrace. 
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Oligonucleotides came from the Iowa IDT. Phosphatidylcholine (PC) and Cholesterol were from 
Avanti. 
N-domain constructs of HKI— Human brain hexokinase (HKI) was cloned into pET-24b 
vector with a polyhistidyl tag at its C-terminus (pET-24b-HKI-10xHis) as reported previously 
(26). Hexokinase mutants were created through PCR modification. An NdeI cut site was created 
at Ala454 in pET-24b-HKI-10xHis using the forward primer, 5’-
GCAGCGGCAAGGGGGCTCATATGGTGACGGCGGTGGC-3’, and its reverse complement. 
N-terminal half HKI plasmid was digested with NdeI and then ligated to produce pET24b-HKI1–
454-10xHis. This plasmid encodes residues 1–454 of HKI with a C-terminal polyhistidyl tag. 
Green Fluorescence Protein (GFP) was incorporated between the C-terminal end of 
HKI1–454 and the polyhistidyl tag by the double digestion using MscI and HindIII cut sites to 
produce pET24b-HKI1–454-GFP-10xHis. A StuI cut site was introduced after the N-terminal first 
26 residues of pET24b-HKI1–454-GFP-10xHis using the forward primer, 5’-
ATTACTTCACGGAGCTGAAGGAAGGCCTTCCATGAATGGATGACCAGGTCAA-3’, and 
its reverse complement. Digestion with StuI and HindIII and ligation to pET24b resulted in 
pET24b-HKI27–454-GFP-10xHis. The N-terminal 26 residues of HKI were removed by double 
digestion using NdeI and StuI and then ligated into pET24b-GFP to produce pET24b-HKI1–26- 
GFP-10xHis. 
Several constructs employed the tetracysteine motif (to be subsequently reacted with 
FlAsH). A tetracysteine motif was inserted between C-terminal end of N-terminal half HKI and 
the polyhistidyl tag using the forward primer, 5’- 
GTCGACAAGCTTGCGGCCTGTTGTCCAGGATGTTGTGCACTCGAGCACCACCAC-3’, 
and its reverse complement. The resulting construct (pET24b-HKI1–454-tetracysteine-10xHis) has 
1-454 residues of HKI followed by the tetracysteine motif and the polyhistidyl tag at C-terminal 
end. A ClaI cleavage site was created after the N-terminal first 26 residues using the forward 
primer, 5’-
ATTGACAAGTATCTGTGTTGTCCAGGATGTTGTCATGCCATGGCATGTATGCCATGC
GGCTCTC-3’, and its reverse complement. A plasmid containing the residues 1–26 of HKI with 
the tetracysteine motif was digested with ClaI and ligated with the pET24b vector to produce 
pET24b-HKI1–26-tetracysteine-10xHis. The construct encodes residues 1–26 of HKI, the 
tetracysteine motif, and a C-terminal polyhistidyl tag. 
60 
 
All plasmid constructs were confirmed by DNA sequencing at the DNA Sequencing 
Facility at Iowa State University. 
Expression and purification of N-domain HKI constructs— E.coli strain BL21 (DE3) 
cells were transformed with plasmids of HKI constructs. Expression and purification HKI 
constructs employed Ni-NTA agarose chromatography as previously described (26). Protein 
purity was monitored by SDS-polyacrylamide gel electrophoresis. The determination of protein 
concentration employed the method of Bradford with bovine serum albumin as a standard (27). 
Cloning of Wild-type human VDAC-1— A plasmid with the coding sequence of human 
VDAC-1 (hVDAC-1) was purchased from Open Biosystems. NdeI and SacI cut sites were 
created in the plasmid using the polymerase chain reaction (PCR) and NdeI primer 
5'CGCGGCAGCCATATGATGGCTGTGCCACCCACG3' and SacI primer 
5'GGACTGGAATTTCAAGCA TCGAGCTCCGTCGACAAGC3'. The PCR product and vector 
pET-24a were digested by NdeI and SacI restriction enzymes. After separation on agarose gel, 
the DNA fragment for hVDAC-1 was ligated to pET-24a. The construct was confirmed by DNA 
sequencing at Iowa State University. 
Expression and purification of hVDAC-1— E.coli strain BL21 (DE3) cells were 
transformed with hVDAC-1 or mutant hVDAC-1 plasmids. The expression and purification 
hVDAC-1 are discussed elsewhere (28, 29). The determination of protein concentration and 
secondary structure employed UV absorbance at 280 nm and CD spectra, respectively. 
Reconstitution of gigantic unilamellar vesicle (GUV) embedding hVDAC-1— Reconstitution of 
GUVs used the dehydration method (30) with modification as described here briefly. 
Composition of GUV employed the major components of the outer mitochondrial membrane, 
phosphatidylcholine (PC) and phosphatidylethanolamine (PE). The lipids were dissolved in 
chloroform, each to a concentration of 0.1 M. 20 µl of this solution was added to a 50 mL round-
bottom flask containing 980 µL of chloroform and 200 µL of methanol. The aqueous phase (7 
mL of 5 mM Hepes, pH7.4) was carefully added along the flask wall. Liposomes formed in the 
aqueous phase. VDAC to be embedded in vesicles were added up to a concentration of 2 µM to 
the aqueous phase prior to evaporation of the organic solvent. The organic solvent was removed 
in a rotary evaporator under reduced pressure at 40 °C and 40 rpm. As a consequence of the 
different boiling temperatures of chloroform and methanol, two major boiling events were 
observed. After evaporation for 2 min, an opalescent fluid was obtained in a volume of about 6.5 
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ml. The resulting aqueous solution contained a high concentration of GUVs, sizes ranging from 
20 tο 70 µm. 
Computational analysis of VDAC recognition sequence of HKI— N-terminal sequences 
in data bases, UniProtKB/Swiss-Prot (release 2013_01 of 09-Jan-13: 538849 entries and 
UniProtKB/TrEMBL (release 2013_01 of 09-Jan-13: 29266939 entries), were scanned using 
ScanProsite (31) for similarities against the mitochondrial recognition element of the HKI 
(residues 1–8). 
Confocal microscopy— 2 µL of freshly prepared vesicle solution was applied to the well 
of a microscope slide, and a cover slide set above the sample. Samples were examined with a 
Leica SP5 X MP confocal/multiphoton microscope system with an inverted microscope front end 
equipped with A HCX PL APO CS 63.0x1.40 OIL UV objective lens. A drop of microscope 
immersion oil (n=1.518) was placed between the cover glass and the tip of the microscope 
objective. The light source was a 250 W halogen lamp, which transmitted incoherent light (400-
700 nm) via a fiber optic light guide to the microscope. The optical sections were acquired in 1 
micron vertical steps. The images were digitized in a format of 512 x 512 pixels (8 bits) and 
stored in the TIFF format. The fluorescence emission and excitation were followed each specific 
fluorophore. Commercial confocal software (Leica) was used for image analysis. 
RESULTS 
Search for the HKI mitochondrial recognition element in other proteins – HKI and HKII 
interact with mitochondria through the first (N-terminal) 26 residues (17, 18).  Some or all of 
these residues form a helix, the N-terminus of which could reach Glu73 of VDAC.  In models of 
membrane-associated VDAC, Glu73 is buried halfway in the mitochondrial outer membrane, 
requiring minimally an α-helix of 8 residues to span the outer leaflet of the mitochondrial outer 
membrane. ScanProsite was used for scanning proteins against a defined motif. The specific 
motif used here are the first eight residues of HKI and HKII: M-I-A-[A or S]-[Q or H]-L-L-A. 
The search revealed HKI and HKII from 32 organisms (Table 1), one predicted membrane 
protein in from Pseudomonas stutzeri (strain A1501), and 43 uncharacterized proteins from 
different organisms. Of the uncharacterized proteins, most come from higher eukaryotes 
(mammals, birds and reptiles), and are likely hexokinases, but the remaining are from species of 
Pseudomonas and have probable homology to that of the predicted membrane protein of 
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Pseudomonas stutzeri (strain A1501). All characterized proteins (all of them HKI or HKII) have 
peptide sequences that make exact matches to the motif. The motif seems restricted to 
hexokinases of higher eukaryotes, suggesting a fundamental purpose in the hexokinase-
mitochondrion interactions. 
TABLE 1. Results from M-I-A-[A or S]-[Q or H]-L-L-A sequence motif search (ScanProsite). 
# Proteins Organisms Seq. (1-8) 
1 Hexokinase-1 Bovine MIAAQLLA 
2 Hexokinase-1 Human MIAAQLLA 
3 Hexokinase-1 Sumatran 
Orangutan 
MIAAQLLA 
4 Hexokinase-1 Rat MIAAQLLA 
5 Hexokinase-2 Grevy's Zebra MIASHLLA 
6 Hexokinase-2 Horse MIASHLLA 
7 Hexokinase-2 Human MIASHLLA 
8 Hexokinase-2 Pig MIASHLLA 
9 cDNA FLJ75392, highly similar to Homo sapiens 
hexokinase II (HKII) mRNA 
Human MIASHLLA 
10 cDNA FLJ78173, highly similar to Homo sapiens 
hexokinase 1 (HK1) mRNA 
Human MIAAQLLA 
11 cDNA FLJ56506, highly similar to Hexokinase-1 (EC 
2.7.1.1) 
Human MIAAQLLA 
12 Hexokinase-2 Horse MIASHLLA 
13 Hexokinase-2 Horse MIASHLLA 
14 Hexokinase-1 Chinese Hamster MIAAQLLA 
15 Hexokinase-1 Naked Mole Rat MIAAQLLA 
16 Hexokinase-1 Sumatran 
Orangutan 
MIAAQLLA 
17 Hexokinase 2 Chimpanzee MIASHLLA 
18 Hexokinase-1 isoform HKI Rhesus Macaque MIAAQLLA 
19 Hexokinase-2 Rhesus Macaque MIASHLLA 
20 Hexokinase-1 isoform HKI Rhesus Macaque MIAAQLLA 
21 Hexokinase 2 Chimpanzee MIASHLLA 
22 Hexokinase 2 Chimpanzee MIASHLLA 
23 Hexokinase 1 Chimpanzee MIAAQLLA 
24 Hexokinase 1 Bovine MIAAQLLA 
25 Hexokinase 1, isoform CRA_d Mouse MIAAQLLA 
26 Hexokinase2 Chicken MIASHLLA 
27 Hexokinase1 Chicken MIAAQLLA 
28 Hk1 protein Western clawed 
frog 
MIAAQLLA 
29 Hexokinase 1a Atlantic Cod MIAAQLLA 
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TABLE 1 Continued 
30 Hk1-A protein African Clawed 
Frog 
MIAAQLLA 
31 Hexokinase 1 Zebrafish MIAAQLLA 
32 Hexokinase 1 Zebrafish MIAAQLLA 
33 Uncharacterized protein Bovine MIAAQLLA 
34 Uncharacterized protein Chicken MIAAQLLA 
35 Uncharacterized protein White Tufted ear 
Marmoset 
MIAAQLLA 
36 Uncharacterized protein White Tufted ear 
Marmoset 
MIAAQLLA 
37 Uncharacterized protein Horse MIAAQLLA 
38 Uncharacterized protein Duckbill Platypus MIAAQLLA 
39 Uncharacterized protein Rhesus Macaque MIASHLLA 
40 Uncharacterized protein White Tufted ear 
Marmoset 
MIASHLLA 
41 Uncharacterized protein Giant Panda MIASHLLA 
42 Uncharacterized protein Northern White-
Cheeked Gibbon 
MIASHLLA 
43 Uncharacterized protein Rabbit MIASHLLA 
44 Uncharacterized protein Lowland Gorilla MIASHLLA 
45 Uncharacterized protein African Elephant MIASHLLA 
46 Uncharacterized protein Tasmanian Devil MIASHLLA 
47 Uncharacterized protein Crab-eating 
Macaque 
MIASHLLA 
48 Uncharacterized protein Small-Eared 
Galago 
MIAAQLLA 
49 Uncharacterized protein Zebra Finch MIAAQLLA 
50 Uncharacterized protein Chicken MIASHLLA 
51 Uncharacterized protein Chicken MIASHLLA 
52 Uncharacterized protein Pig MIAAQLLA 
53 Uncharacterized protein Thirteen-Lined 
Ground Squirrel 
MIAAQLLA 
54 Uncharacterized protein Dog MIAAQLLA 
55 Uncharacterized protein Chinese Softshell 
Turtle 
MIAAQLLA 
56 Uncharacterized protein Mouse MIAAQLLA 
57 Uncharacterized protein Mouse MIAAQLLA 
58 Uncharacterized protein Western clawed 
frog 
MIASHLLA 
59 Uncharacterized protein Three-Spined 
Stickleback 
MIAAQLLA 
60 Uncharacterized protein Three-Spined 
Stickleback 
MIAAQLLA 
61 Uncharacterized protein Medaka Fish MIAAQLLA 
62 Uncharacterized protein Japanese 
Pufferfish 
MIAAQLLA 
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VDAC embedded in gigantic unilamellar vesicles— The dehydration method produced 
vesicles in the presence and absence of VDAC in reproducible amounts and size. GUVs 
produced in the absence of VDAC did not localized TNP-ATP in contrast to GUVs produced in 
the presence of VDAC (Fig. 1). Previous studies show that TNP-ATP binds to VDAC with high 
affinity (Chapters 2 & 3 of this thesis). The outer ring of fluorescence is consistent with the 
localization of TNP-ATP in the membrane (only in the presence of VDAC), and is a 
consequence of curvature of vesicles and a focal plane of thickness smaller than the diameter of 
the vesicle. This result indicates VDAC has become embedded in the membrane of GUVs so that 
its TNP-ATP binding site is accessible to solution. 
Localization of interactive proteins— The determination of whether HKI can bind to GUVs with 
and without VDAC involved a set of HKI constructs involving two fluorescence labels. 
Nonspecific binding of polyhistidyl-tagged HKI to the mitochondrial outer membrane occurs 
(Chapter 2 of this thesis). In order to limit membrane binding to the N-terminal tail of HKI, the 
N-terminal half was tagged with the green fluorescent protein (GFP) and alternatively the FlAsH 
tagged tetracysteine motif (Fig. 2). Although GFP is a commonly employed fluorophore, it might 
TABLE 1Continued 
63 Uncharacterized protein Japanese 
Pufferfish 
MIAAQLLA 
64 Uncharacterized protein Japanese 
Pufferfish 
MIAAQLLA 
65 Uncharacterized protein Japanese 
Pufferfish 
MIAAQLLA 
66 Uncharacterized protein West Indian 
Ocean Coelacanth 
MIAAQLLA 
67 Uncharacterized protein Spotted Green 
Pufferfish 
MIAAQLLA 
68 Uncharacterized protein Spotted Green 
Pufferfish 
MIAAQLLA 
69 Uncharacterized protein Nile Tilapia MIAAQLLA 
70 Uncharacterized protein Nile Tilapia MIAAQLLA 
71 Predicted membrane protein. (strain A1501) Pseudomonas MIAAHLLA 
72 Uncharacterized protein (strain DSM 4166 / CMT.9.A) Pseudomonas MIAAHLLA 
73 Uncharacterized protein 
(strain:ATCC17588/DSM5190/CCUG11256/JCM5965/L
MG11199/NCIMB11358/Stanier221) 
Pseudomonas MIAAHLLA 
74 Uncharacterized protein CCUG 29243 Pseudomonas MIAAHLLA 
75 Uncharacterized protein TS44 Pseudomonas MIAAHLLA 
76 Uncharacterized protein KOS6 Pseudomonas MIAAHLLA 
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still bind nonspecifically to the GUV or even VDAC. Hence, in order to confirm binding due 
exclusively to the N-terminal tail of HKI, a “tail-less” N-terminal HKI tagged with GFP served 
as a negative control. 
The FlAsH tagged tetracysteine motif provided an alternative experimental approach that 
confirmed the behavior of the GFP-tagged constructs. Nonspecific interactions due to the FlAsH-
modified tetracysteine motif were ruled out by the absence of membrane-associated fluorescence 
in the presence of the “tail-less” N-terminal half HKI with the FlAsH-modified tetracysteine 
motif. The results (Fig. 2) taken together show that the GUV must have VDAC in order to bind 
an HKI-construct, and that the HKI construct must have its first 26-residues in order for binding 
to occur. Moreover, binding to the GUV with VDAC occurs with just the first 26 residues of 
HKI. 
 
FIGURE 1. GUV captures VDAC. Panels A, B, and C represent illuminating fluorophores, 
normal light view, and the superposition of images A and B, respectively. The fluorophore is 
TNP-ATP with at excitation 409 nm and emission at 530 nm. 
If images of Fig. 1 & 2 are scanned, and transformed to relative fluorescence intensities 
(observed intensity relative to background intensity). The distribution of relative fluorescence 
through a diametric cross-section of the GUV appears as in Fig 3. Two peaks represent each 
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edge of the GUV, with background fluorescence taken outside the GUV. Comparison of peak 
fluorescence levels from different samples (Fig. 4) are complicated by three considerations.  
Firstly, fluorescence intensity is a nonlinear function of fluorophore concentration. Hence, peak 
intensities at saturation are insensitive to increases in fluorophore concentration.  Secondly, 
fluorescence intensity will vary with vesicle size. Larger vesicles would elevate fluorescence 
intensity in the peaks due to less membrane curvature and more membrane perpendicular to the 
pathway of the fluorescence scan. Vesicles used in data collection are approximately of the same 
size (60±10 microns), so that differences greater 20% should reflect different loads of the protein 
on the membrane.  Thirdly, the amount of protein construct added to each sample is the same, 
but the molecular weight of each construct differs.  Hence, the molar concentration is different.  
In fact, the molar concentration of N-terminal HKI tagged with GFP is approximately one-half of 
that of the tail tagged with GFP.  The variation in peak fluorescence for the GFP constructs 
indicates N-terminal HKI tagged with GFP reaches a substantially higher level than the 26-
residue tail tagged with GFP. 
 
FIGURE 2. Interaction between VDAC-embedded GUVs with N-terminal HKI fluorophores. 
(Panel 1) N-terminal half HKI tagged with GFP (excitation 488 nm and emission 509 nm). A, B 
and C represent the illuminating fluorophore view, normal light view, and the superimposition of 
A and B, respectively. (Panel 2) N-terminal half HKI with the FlAsH-modified tetracysteine 
motif (excitation 508 nm and emission 528 nm). (Panel 3) N-terminal 26 residues of HKI tagged 
with GFP. (Panel 4) N-terminal half HKI (without the first 26 residues) tagged with GFP 
(excitation 488 nm and emission 509 nm). (Panel 5) N-terminal 26 residues of HKI tagged with 
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FlAsH-modified tetracysteine without VDAC at GUV. (Panel 6) N-terminal half HKI tagged 
with GFP added to GUV without VDAC. In each instance, 2 µM of HKI construct was added to 
the well of the microscope slide. VDAC came from the same preparation. GUVs were prepared 
freshly as described in the Methods Section. 
 
FIGURE 3. Intensity scan along the diameter of a GUV with bound N-terminal HKI tagged with 
GFP. Fluorescence of GFP-tagged N-terminal-HKI localizes to the membrane giving the 
observed pattern. 
 
FIGURE 4. Relative peak intensity of bound HKI constructs. Relative peak intensity captured 
by the analysis presented in Fig. 3. 
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Release of N-terminal HKI by glucose 6-phosphate and ATP— TNP-nucleotides, 
nucleotides, and glucose 6-phosphate release HKI from the outer membrane of the 
mitochondrion (Chapter 2, this thesis). The release phenomenon is pH dependent, with 
maximum binding of HKI (and release) occurring at pH 7.4. The overlap of the 
excitation/emission spectra for TNP-nucleotides with that of GFP- or FlAsH-tagged fluorophores 
preclude the use of TNP nucleotides as release agents; however, other effective release agents 
(ATP and glucose 6-phosphate) do not interfere. GFP fluorescence decreases in response to 
additions of glucose 6-phosphate and ATP (Fig. 5). Fluorescence intensities are determined as 
above (Figs. 3 & 4), and are limited by the nonlinear relationship between fluorescence and 
fluorophore concentration and variation in vesicle size (Fig. 6); however, GFP fluorescence 
clearly diminishes in response to releasing ligand.  
 
 
 
FIGURE 5. Effect of glucose 6-phosphate and ATP on fluorescence intensities from N-terminal 
HKI tagged with GFP. N-terminal half HKI tagged with GFP (A). N-terminal half HKI tagged 
with GFP followed by the addition of 10 mM glucose 6-phosphate (B). N-terminal half HKI 
tagged with GFP followed by the addition of 20 mM glucose 6-phosphate (C). N-terminal half 
HKI tagged with GFP followed by the addition of 10 mM ATP (D). Excitation 488 nm and 
emission 509 nm. The pH of each added ligand was adjusted to 7.4 (equal to the pH of the buffer 
used in making the GUV). 
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FIGURE 6. Comparison glucose 6-phosphate (G6P) and ATP in releasing HKI constructs. The 
left-most bar represents the fluorescence due to GUV-bound N-terminal half HKI tagged with 
GFP, whereas the other represent fluorescence remaining after the addition of the releasing 
ligand. 
 
 
 
FIGURE 7. Effect of glucose 6-phosphate and ATP on fluorescence intensities from N-terminal 
HKI tagged with FlAsH-modified tetracysteine. N-terminal half HKI tagged with FlAsH-
modified tetracysteine (A). N-terminal half HKI tagged with FlAsH-modified tetracysteine 
followed by the addition of 10 mM glucose 6-phosphate (B). N-terminal half HKI tagged with 
FlAsH-modified tetracysteine followed by the addition of 20 mM glucose 6-phosphate (C). N-
terminal half HKI tagged with FlAsH-modified tetracysteine followed by the addition of 10 mM 
ATP (D).  Green blotches represent protein aggregates.  Excitation 508 nm and emission 528 nm.  
The pH of each added ligand was adjusted to 7.4 (equal to the pH of the buffer used in making 
the GUV). 
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FIGURE 8. Comparison of glucose 6-phosphate (G6P) and ATP in releasing HKI constructs. 
The left-most bar represents the fluorescence due to GUV-bound N-terminal half HKI tagged 
with FlAsh, whereas the others represent fluorescence remaining after the addition of the 
releasing ligand. 
The release of N-terminal HKI tagged with FlAsH-modified tetracysteine is comparable 
to the GFP construct (Figs. 7 & 8). These data indicate more than a 4-fold loss of fluorescence 
intensity relative to that of N-terminal half HKI tagged with FlAsh modified tetracysteine. 
Release of the 26-residue N-terminal tail of HKI— Glucose 6-phosphate and ATP release 
HKI from the mitochondrion (and also GUVs containing VDAC); however, the mechanism of 
release from the mitochondrion differs.  Glucose 6-phosphate releases HKI from the 
mitochondrion by binding to the glucose 6-phosphate binding site in the N-terminal half of HKI 
(32), whereas ATP releases HKI by binding to VDAC (Chapters 2&3, this thesis).  The tagged 
constructs having just the 26-residue N-terminal tail of HKI (and lacking the glucose 6-
phosphate binding site) should not be released by glucose 6-phosphate.  Indeed, this appears to 
be the case as the 26-residue N-terminal tail tagged with GFP remains bound in the presence and 
absence of glucose 6-phosphate (Figs 9 & 10).  ATP, however, diminishes bound construct, 
although the change in fluorescence is small relative to the variation observed over samples 
having from 0–20 mM glucose 6-phosphate. 
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FIGURE 9. Effect of glucose 6-phosphate and ATP on membrane bound constructs 
incorporating the 26-residue N-terminal tail of HKI. Constructs are tagged with GFP (excitation, 
488 nm; emission, 509 nm). From left to right, no glucose 6-phospahte, 10 mM glucose 6-
phosphate, 20 mM glucose 6-phosphate and 10 mM ATP.  All pictures were taken under the 
illuminating fluorophores. 
 
FIGURE 10. Comparison of glucose 6-phosphate (G6P) and ATP in releasing 26-residue N-
terminal HKI constructs. The left-most bar represents the fluorescence due to GUV-bound 26-
residue N-terminal HKI tagged with GFP, whereas the others represent fluorescence remaining 
after the addition of the releasing ligand. 
DISCUSSION 
The results represent the first demonstration that VDAC alone is necessary and sufficient 
to localize HKI to the membrane. Other factors, such as the involvement of pro-apoptotic 
proteins, post-translational modification of VDAC, and polarization of the mitochondrial outer 
membrane, probably modulate HKI binding to the mitochondrion, but the fundamental 
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characteristics of the VDAC-HKI interaction are determined primarily by elements of VDAC 
and HKI. 
The N-terminal sequence motif of HKI and HKII is limited primarily to proteins of 
higher eukaryotes (this study). Proteins that have the N-terminal sequence motif have either been 
characterized biochemically as hexokinases or have high sequence identity to a characterized 
hexokinase. This observation, combined with a two-component interaction involving HKI and 
VDAC, suggests a specific binding site on VDAC for the N-terminal tail of HKI (and HKII). 
Studies of Maskey et al. (MS thesis), implicate residue positions 1, 4 and 8 in the interaction 
between the N-terminal tail of HKI and VDAC. Positions 1, 4 and 8 define a contiguous face of 
an α-helix that could mate with a complementary surface of VDAC. In fact, the mutation of the 
N-terminal methionine of HKI (Met1Leu) reduces binding affinity to the mitochondrion by 10-
fold. The complementary surface of VDAC that recognizes the N-terminal tail of HKI is 
unknown; however, Glu73 lies on the outer surface of the VDAC barrel, and would localize 
approximately midway between the outer and inner leaflets of the membrane bilayer.  A three-
turn α-helix (approximately 16 Å in length) would extend midway to Glu73. Coarse-grain 
modeling localizes the 1-4-8 face of the α-helix to the exterior of the VDAC barrel in the vicinity 
of Glu73 (Maskey, MS thesis). 
The GUV system presented here could be a useful tool in the systematic investigation of 
interactions of HKI (and HKII) with VDAC. The GUV has but one component (VDAC) 
embedded in its membrane. Hence, any protein that binds to the GUV-VDAC system but not to 
GUV alone, must bind directly to VDAC or to a membrane structure maintained by VDAC. 
Hence, the effect of VDAC mutations on the binding of HKI, along with supporting CD spectra 
to verify the VDAC fold (Chapter 3, this thesis), could map out the binding site on VDAC for 
HKI. Currently the only approach to the characterization of VDAC mutants is by change in 
phenotype. The mutation of Glu73 of VDAC to glutamine in yeast results in a cell line that is 
barely viable, and in fact probably survives only because expression levels of wild-type VDAC 
(VDAC-1) are not eliminated entirely and other genes of VDAC (VADC-2 and -3) may 
complement the Glu73Gln mutation. 
Pig liver mitochondria comparably bind N-terminal half HKI and wild-type HKI 
(Chapter 2, this thesis) using an ELISA assay; however, these binding experiments are 
complicated by variations in mitochondrial preparations and in the stability of HKI constructs. 
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Specifically, the polyhistidyl-tagged wild-type HKI has a half-life of 48 hours (as measured by 
specific activity). The instability is due to the polyhistidyl tag attached to the C-terminal half, 
and results in nonspecific binding (binding that cannot be reversed by glucose 6-phosphate or 
nucleotides). The constructs used here eliminate the C-terminal half of HKI, eliminating catalytic 
activity as readout of HKI levels, but providing a means of directly visualizing the binding of 
HKI to VDAC vesicles. 
HK is the “guardian of the mitochondria” (17), controlling the open and closed state of 
VDAC. Indeed, the addition of HKI terminates ion conductance through VDAC in patch-clamp 
experiments. The VDAC pore itself, however, can open to a size no larger than the diameter of 
its barrel (<36 Å) and that size is insufficient to pass cytochrome c. The flow of cytochrome c 
out of the mitochondrion is the hallmark of the mitochondrial pathway of apoptosis. Presumably, 
multiple molecules of VDAC cluster into a complex in order to create a sufficiently large pore. 
Pro-apoptotic proteins presumably stabilize this macro-pore (some have called this the 
permeability transition pore), whereas the HKI complex of VDAC antagonizes macro-pore 
formation. The TNP-ATP bound state of VDAC exhibits uniform fluorescence, without punctate 
patterns indicative of VDAC clusters (Fig. 1). The addition of N-terminal half HKI tagged with 
GFP makes a punctate pattern indicative of HKI clusters (Fig. 2); however, fluorescence-
emission clusters could simply be indicative of nonspecific aggregation. The punctate pattern is 
not evident in images that expose VDAC-GUVs to N-terminal half HKI tagged with FlAsH-
modified tetracysteine. The experiments here do not indicate the formation of VDAC clusters, 
and in fact, experiments were not designed to produce such clusters. 
VDAC cluster formation may also be sensitive to the orientation of membrane-embedded 
VDAC. Presumably 50% of VDAC molecules spontaneously insert into the membrane of GUVs 
with their true outer face directed inward (backward insertion). If so, then the mixture of two 
differently oriented populations of VDAC might interfere with macro-pore formation. 
REFFERENCES 
1.Wilk, S. (2005) Apoptosis. Sci. STKE. 285, tr16. 
2.Czerski, L; Nunex, G. (2004) J. Mol. Cell. Cardiol. 37, 643-52. 
3.Lemasters, J J; Holmuhamedov, E. (2006) Biochim. Biophys. Acta. 1762, 181-90. 
4.Tsujimoto, Y; Shimizu, S. (2002) Biochemie. 84, 187-93. 
74 
 
5.Vyssokikh, M Y; Brdiczka, D. (2003) Acta. Biochim. Pol. 50, 389-404. 
6.Abu-Hamad, S; Arbel, N; Calo, D; Arzoine, L; Israelson, A; Keinan, N; Ben-Romano, R; 
Friedma, O; Shoshan-Barmatz, V. (2009) J. Cell. Sci. 122, 1906-16. 
7.Tajeddine, N; Galluzzi, L; Kepp, O; Hangen, E; Morselli, E; Senovilla, L; Araujo, N; Pinna, G; 
Larochette, N; Zamzami, N; Modjtahedi, N; Harel-Bellan, A; Kroemer, G. (2008) Oncogene. 27, 
4221-31. 
8.Yuan, S; Fu, Y; Wang, X; Shi, H; Huang, Y; Song, X; Li, L; Song, N; Luo, Y; (2008) FASEB. 
J. 22, 2809-20. 
9.Madesh, M; Hajnoczky, G. (2001) J. Cell. Biol. 155, 1003-10. 
10.Shimizu, S; Matsuoka, Y; Shinohara, Y; Yoneda, Y; Tsujimoto, Y. (2001) J. Cell Biol. 152, 
237-50. 
11.Zheng, Y; Shi, Y; Tian, C; Jiang, C; Jin, H; Chen, J; Almasan, A; Tang, H; Chen, Q. (2004) 
Oncogene. 23, 1239-47. 
12.Abu-Hamad, S; Zai, H; Israelson, A; Nahon, E; Shoshan-Barmatz, V. (2008) J. Biol. Chem. 
283(19), 13482-90. 
13.Ghosh, T; Pandey, N; Maitra, A; Brahmachari, S K; Pillai, B. (2007) PLoS. ONE. 2, e1170. 
14.Godbole, A; Varghese, J; Sarin, A; Mathew, M K. (2003) Biochim. Biophys. Acta. 1642. 87-
96 
15.Lu, A J; Dong, C W; Du C S; Zhang, Q Y. (2007) Fish. Shellfish. Immunol. 23, 601-13 
16.Zaid, H; Abu-Hamad, S; Israelson, A; Nathan, I; Shoshan-Barmatz, V. (2005) Cell. Death. 
Differ. 12, 751-60. 
17.Robey, R B; Hay, N. (2005) Cell. Cycle. 4, 654-58. 
18.Neumann, D; Bückers, J; Kastrup, L; Hell, S W; Jakobs, S. (2010) PMC. Biophys. 3, 1-15. 
19.Perevoshchikova, I V; Zorov, S D; Kotova, E A; Zorov, D B; Antonenko, Y N. (2010) FEBS. 
Lett. 584, 2397-402. 
20.Arzoine, L; Zilberberg, N; Ben-Romano, R; Shoshan-Barmatz, V. (2009) J. Biol. Chem. 284, 
3946-55. 
21.Shoshan-Barmatz, V; Zakar, M; Rosenthal, K; Abu-Hamad, S. (2009) Biochim. Biophys. 
Acta. 1787, 421-30. 
22.Azoulay-Zohar, H; Israelson, A; Abu-Hamad, S; Shoshan-Barmatz, V. (2004) Biochem. J. 
377, 347-55. 
75 
 
23.Yehezkel, G; Hadad, N; Zaid, H; Sivan, S; Shoshan-Barmatz, V. (2006) J. Biol. Chem. 281, 
5938-46. 
24.Yehezkel, G; Abu-Hamad, S; Shoshan-Barmatz, V. (2007) J. Cell. Physiol. 212, 551-61. 
25.Rostivtseva, T K; Kazemi, N; Weinrich, M; Bezrukov, S M. (2006) J. Biol. Chem. 281, 
37496-506. 
26.Skaff, D A; Kim, C S; Tsai, H J; Honzatko, R B; Fromm, H J. (2005) J. Biol. Chem. 280, 
38403-9. 
27.Bradford, M M. (1976) Anal. Biochem. 72, 248-254.  
28.Yehezkel, G; Abu-Hamad, S; Shoshan-Barmatz, V. (2007) J. Cell. Physiol. 212, 551-61. 
29.Engelhardt, H; Meins, T; Poynor, M; Adams, V; Nussberger, S; Welte, W; Zeth, K. (2007) J. 
Membrane Biol. 216, 93-105. 
30.Moscho, A; Orwar, O; Chiu, T D; Modi, P B; Zare, N R. (1996) Proc. Natl. Acad. Sci. U.S.A 
93, 11443-447. 
31.De Castro, E; Sigrist, C J A; Gattiker, A; Bulliard, V; Langendijk-Genevaux P S; Gasteiger, 
E; Bairoch, A; Hulo, N. (2006) Nucleic Acids Res. 34, W362-5. 
32. Skaff, D A; Kim, C S; Tsai, H J; Honzatko, R B; Fromm, H J. (2005) J. Biol.Chem. 280, 
38403-9. 
76 
 
CHAPTER 5: COMBINED HALIDE AND ADDUCT STABILIZATION OF β-
KETOACYL-(ACYL-CARRIER-PROTEIN) SYNTHASE III 
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Running title: Importance of binding compounds at FabH active site 
Keywords: FabH; CPM; Acetyl CoA; Malonyl-CoA; fluorescence 
Background: FabH governs the principal priming reaction for fatty-acid biosynthesis in 
Escherichia coli, and efforts to manufacture non-native fatty acids through the introduction of 
engineered enzymes must take into account enzyme stability in vivo. 
Results: The Cys112 acetyl-adduct form of FabH in the presence of halide anions optimizes the 
stability of the enzyme. 
Conclusion: FabH in vivo is most likely present as the acetyl adduct of Cys112, which is an 
intermediate state of a reaction cycle. 
Significance: Engineering FabH in order to prime fatty-acid biosynthesis with variants of the 
acetyl group must consider the chemical and conformational stability of the enzyme intermediate. 
 
ABSTRACT 
β-Ketoacyl–(acyl-carrier-protein) synthase III (FabH) catalyzes the first condensation 
reaction of fatty acid biosynthesis. Highly purified FabH from Escherichia coli is unstable at 
elevated concentrations and precipitates irreversibly from solution. Stability problems aside, the 
enzyme can be crystallized, resulting in atomic-resolution structures. The basis of FabH 
instability is explored here by experiments in x-ray crystallography and thermal denaturation. 
Conditions of crystallization enhance the thermal stability of FabH through a nonspecific 
mechanism; however, the presence of halide ions (chloride and bromide), enhances the 
thermostability of FabH by specific mechanisms subject to saturation.  FabH crystallizes readily 
when prepared rapidly from an E. coli expression system.  Such crystals have well-defined 
electron density for an acetyl adduct, covalently linked to the active-site cysteine (Cys112). The 
covalent adduct forms a charged complex with a chloride anion that sterically prevents 
hydrolysis of the acetyl adduct. Co-crystallization of FabH with acetyl-CoA provides a clear and 
detailed image of a substrate/product complex of FabH to a resolution of 1.4 Å, however, the 
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active site has a mixture of Cys112 with an acetyl adduct, and Cys112 without adduct but in a 
disulfide linkage to the thiol group of CoA. Finally, a partially unfolded form of FabH has been 
trapped in crystals. Evidently, FabH achieves relatively high levels of stability as the acetyl 
adduct of Cys112, paired with a suitable anion, such as a chloride. The “resting” state of the 
enzyme in vivo may be the intermediate form after the priming reaction and before its reaction 
with malonyl-acyl carrier protein. 
INTRODUCTION 
A significant effort in the engineering of enzymes and biosynthetic pathways is necessary 
in order for bio-renewable chemicals to replace or provide alternatives to petroleum-derived 
chemicals. The biosynthesis of a diverse set of natural (1, 2) or unnatural (3, 4) compounds is 
catalyzed by condensing enzymes. Many of these enzymes are part of the Type II fatty acid 
synthase system, which is the primary pathway for the production of fatty acids in bacteria. In 
Escherichia coli fatty-acid biosynthesis involves enzymes FabB, FabF, and FabH (β-ketoacyl-
(acyl-carrier-protein) synthase-I, -II and -III respectively). FabH is distinct from FabB and FabF 
because it uses acetyl-coenzyme A (acetyl-CoA) over acyl-ACP (acyl carrier protein) in the 
primary in vivo initiation reaction of fatty-acid biosynthesis (5, 6). Acetyl-CoA first transfers its 
acetyl moiety to the sulfur atom of FabH Cys112, releasing CoA. Malonyl-ACP then binds to 
FabH and undergoes decarboxylation, generating a resonance-stabilized carbanion that reacts 
with the acetyl adduct attached to Cys112. The net reaction is the condensation of malonyl-ACP 
and acetyl-CoA to product acetoacetyl-ACP (9). 
FabH is ideally positioned as a regulator of the fatty acid biosynthesis in Escherichia coli 
(7, 8). Fatty acids produced from biosynthetic pathways are used in the production of retail fuels 
(7); however, procedures to scale-up microbial production using alternative carbon sources 
requires extensive engineering of metabolic pathways and enzymes (10-15). The development of 
dynamic sensor-regulator systems for non-natural products derived from fatty acids also presents 
challenges (16). 
Molecular dynamic simulations of FabH, with and without bound ligands, suggest the 
free enzyme (no bound ligands and no adduct) is the least stable form of FabH (17). Hence, if 
engineered forms of FabH are to be used in the production of non-natural fatty acids, a strategy 
to stabilize FabH constructs in vivo while permitting catalysis is a necessary attribute. Wild-type 
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FabH, however, is unstable, and at elevated concentrations precipitates irreversibly from solution. 
The instability of the wild-type enzyme will likely hinder efforts in protein engineering and the 
use of FabH in the biosynthesis of novel fatty-acids. In this study, x-ray crystallography, thermal 
denaturation and enzyme kinetics are used to explore factors critical to the stability of FabH. 
Rapid isolation of FabH from E. coli yields the acetyl adduct of Cys112, observed in crystal 
structure determinations. The unexpected stability of the acetyl adduct of Cys112 is linked to the 
presence of a chloride ion, which protects the acetyl adduct from hydrolysis and thereby guards 
against the inadvertent oxidation of Cys112. Stability of any mutant form of FabH would 
necessarily include a mechanism to protect its key active site residue. 
EXPERIMENTAL PROCEDURES 
Materials— Acetyl Coenzyme A (Acetyl-CoA), Malonyl Coenzyme A (Malonyl-CoA), 
7-Diethylamino-3-(4'-maleimidylphenyl)-4-methylcoumarin (CPM) and Diethylaminoethyl 
(DEAE)–sepharose came from Sigma. Kanamycin sulfate was from Invitrogen. 
Diethylaminoethyl (DEAE) – sepharose, Toyopearl HW-55 was from Tosoh bioscience. 
Isopropyl-1-thio-β-D-galactopyranoside (IPTG) came from Anatrace. Oligonucleotides were 
from the Iowa IDT. 
Cloning of β-ketoacyl-(acyl carrier protein) synthase III and β-ketoacyl-(acyl carrier 
protein) synthase III mutants— β-Ketoacyl-(acyl carrier protein) synthase III (FabH) was cloned 
into a pET-29a vector. FabH mutants were created through PCR modification. A serine residue 
was introduced at position 112 (C112S mutation of FabH) by using the forward primer, 5’-
CATTTGACGTTGCAGCAGCCAGCGCAGGTTTCACCTATGCATT-3’, and its revers 
complement. The construct was confirmed by DNA sequencing facility at Iowa State University. 
Expression and purification of FabH— FabH expression and purification follows 
protocols in the literature (18) with modifications. E.coli strain BL21 (DE3) cells were 
transformed with FabH plasmids. Transformed cells were grown at 37 °C in a shaking incubator 
until OD600 reached 0.9 and then induced with 0.5 mM IPTG. At the moment of induction, 
temperature was reduced to 18 °C. After 16–18 hrs, cells were pelleted and re-suspended in 20 
mL lysis buffer (25 mM Tris-HCl, 50 mM NaCl, 5 mM DTT, pH = 7.5). The cell suspension was 
sonicated three times at 40% of full amplification for 1.5 min. Cell debris were removed from the 
lysate by centrifugation at 16,000 rpm for 1 hr at 4 °C. The clarified lysate was applied to HPLC 
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DEAE column and followed by a linear gradient from 50 mM to 1 M NaCl using lysis buffer 
conditions. Fractions containing FabH as determined by SDS–PAGE were concentrated to 5 mL 
using a 10 kDa-cutoff ultrafiltration membrane (Millipore) and applied to Toyopearl HW-55F 
column (Tosoh). The HW-55F column was run at a flow rate of 1 mL/min. Buffer used was 100 
mM NaCl, 25 mM Hepes, 5 mM DTT, pH = 7.0. The fractions containing FabH were 
determined by SDS-PAGE. 
Expression and purification of holoACP— Holo-ACP expression and purification also 
follow protocols with modifications (18). Holo-ACP was expressed in E. coli BL21 (DE3) cells 
harboring a pETDuet™-vector (EMD-Millipore) containing the apo-ACP and holo-ACP 
synthase genes under control of individual T7 promoters. Apo-ACP was cloned into BamHI and 
EcoRI of the first multiple cloning site (MCS) while holo-ACP synthase was inserted into the 
NdeI and XhoI restriction sites in the second MCS of the pETDuet™ vector. The holo-ACP 
expression cassette includes a His-tag at the N-terminus and the holo-ACP synthase cassette 
includes no modifications. E. coli cells were transformed with the protein expression vector and 
grown to OD600 = 0.9 at 37 °C in a shaking incubator and then induced with 0.5 mM IPTG. At 
the moment of induction, the temperature was reduced to 18 °C. After 16 hrs cells were pelleted 
and re-suspended in 25 mL lysis buffer (20 mM Tris-HCl, 500 mM NaCl, 1 mM β-
mercaptoethanol pH = 8.1). The cell suspension was sonicated three times at 40% of maximum 
amplication for 1.5 min. Cell debris were removed from the lysate by centrifugation at 16,000 
rpm for 1 hr at 4 °C. The supernatant was applied to nickel-NTA column (Qiagen) pre-
equilibrated with lysis buffer. The column was washed with 25 mL of the base buffer 20 mM 
Tris, 500 mM sodium chloride, 1 mM β -mercaptoethanol, pH 8.1, then washed again with 25 
mL of the base buffer plus 5 mM imidazole, followed by 25 mL of the base buffer plus 25 mM 
imidazole. Protein was eluted with a buffer consisting of the base buffer plus 150 mM imidazole. 
Fractions were analyzed by a 15% SDS–PAGE gel. Fractions containing holo-ACP as 
determined by SDS–PAGE were concentrated to 5 mL using a 3 kDa-cutoff ultrafiltration 
membrane (Millipore) and applied to Toyopearl HW-55F column (Tosoh). The HW-55F column 
was run at a flow rate of 1 mL/min. The buffer was 100 mM NaCl, 25 mM Hepes, pH 7.5. The 
fractions containing holo-ACP were determined by SDS-PAGE. 
FabH activity assays— A fluorometric assay was adapted (19) to monitor the appearance 
of CoA via a reaction of a fluorescent reagent 7-diethylamino-3-(4-maleimidophenyl)-4-
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methylcoumarin (CPM) with the newly formed CoA thiol. The FabH assay was conducted with 
50 µM malonyl-CoA, 10 µM CPM, and 50 mM Hepes buffer, pH 7.0, at 25 °C in a volume of 1 
mL. Acetyl-CoA and FabH concentrations ranged from 20 to 100 µM and 0.5 to 2 µM, 
respectively. Fluorescence was measured with excitation at 384 nm and emission at 470 nm 
using a SLM 4800/8000 Spectrophotometer. 
FabH ThermoFluor Assays— The quantitative real-time PCR (qPCR) system 
StepOnePlus was used to run Protein Thermal Shift™ assays to screen for buffer conditions that 
affect the thermal stability of FabH. FabH (2 µg) in 20 mM Hepes pH 7.0 with 5X Sypro Orange 
was combined in wells of a 96-well PCR reaction plate with varying salt concentrations (0–1.2 
M). Temperature was scanned from 25 to 95 °C at a rate of 1 °C per minute. 
FabH crystallizations and data collections— FabH crystals were grown by the hanging-
drop vapor diffusion in 96-well sitting-drop plates. FabH (10–20 mg/mL) in 20 mM Hepes pH 
7.0, 100 mM NaCl was combined with the well solutions in a 1:1 ratio to give a final droplet size 
of 3 µl. The ratio of solutions was varied when substrates and/or acyl carrier protein were added, 
but the drop size did not appear to affect the quality or the size of the crystals. The trays were 
equilibrated at room temperature. Prior to data collection, crystals were looped and immediately 
flash-frozen in liquid nitrogen. All diffraction data were collected at 100 K using a MAR300 
CCD detector on the Advanced Photon Source beamline 23-ID-B (GM/CA-CAT). At a crystal-
to-detector distance of 350 mm, 180 frames were collected using an oscillation range of 1 degree 
and a 10–20 μm beam size. Data were processed using HKL-3000 (20). Additional analysis, 
molecular replacement and refinement were performed using PHENIX (21). 
RESULTS 
Conditions that stabilize FabH— Solution conditions must stabilize a protein in order to 
facilitate crystal nucleation and growth. Conversely, the successful growth of a protein crystal 
infers a condition that stabilizes the protein. A screen for successful growth conditions often vary 
concentrations of polyethylene glycol (PEG), halide salts, ammonium sulfate, and also pH. 
Given that FabH (and any engineered form of FabH) must be stable under physiological 
conditions, the pH is fixed at 7.0. The systematic variation in the concentration of PEG was not 
pursued because at concentration beyond 10% (w/v) PEG, the thermal denaturation assay gave 
no signal indicative FabH unfolding (data not shown). The variation of halide and ammonium 
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sulfate concentration, however, did indicate increases in thermal denaturation temperature as salt 
concentration increased (Fig. 1). The mechanism of stabilization, however, was not the same for 
each salt. NaBr, for instance, exhibits a curve consistent with a specific binding site for Br– or 
Na+ (Kd = 60±10 mM for wild-type FabH), with little or no nonspecific binding by either Br
– or 
Na+ at higher concentrations.  The effects of NaCl and ammonium sulfate on the other hand, are 
consistent with multiple binding sites for the anions (as Na+ had no effect at high concentrations 
when introduced as NaBr).  In the presence of ammonium sulfate, wild-type FabH and C112S 
FabH produced isomorphous crystals (same R32 space group and unit cell parameters); however, 
crystals of C112S FabH diffracted to higher resolution (~2 Å) relative to the wild-type enzyme 
(~2.8 Å).  The difference in the crystal quality correlate well with the difference in thermal 
stabilities of wild-type and C112S FabH (Fig. 2). The serine mutant has higher stability than wild 
type FabH regardless of salt concentration, indicating a stabilization effect of approximately 4 °C 
due to a change in a single atom. 
Influence of sodium chloride on FabH activity— FabH activity is assayed by the 
liberation of CoA from acetyl-CoA. Malonyl-CoA cycles the enzyme back to its free form by its 
reaction with the enzyme-adduct formed when free enzyme reacts with acetyl-CoA (priming 
reaction). In initial velocity kinetics, acetyl-CoA concentration varied from 20 to 100 µM, 
whereas the concentration of malonyl-CoA (second substrate) was fixed at 50 µM. Data and 
calculated constants are in Fig. 3 and Table 1. Specific activity (4 µmol/min/mg) and Km (0.04 
mM) are close to literature values (5.9 µmol/min/mg and 0.04 mM respectively) (5, 22). FabH 
activity is modeled by the Ping-Pong mechanism in an approach-to-equilibrium assay to 
determine NaCl inhibition using DynaFit. FabH with a ping-pong mechanism can exist in two 
states, E and a chemically modified form of the enzyme E*. The modified enzyme is hereafter 
called the adduct form of FabH. In such mechanisms, the first substrate, acetyl-CoA, binds, 
changes the enzyme to E* by transferring the acetyl group to the active site, and is then released 
as CoA. Only after the first substrate is released can secondary substrate, malonyl-CoA, bind and 
react with the acetylated enzyme, regenerating the unmodified E form. 𝐸𝐸 + 𝐴𝐴 → 𝐸𝐸𝐴𝐴 → 𝐸𝐸∗𝑃𝑃 → 𝐸𝐸∗  → 𝐸𝐸∗𝐵𝐵 → 𝐸𝐸 + 𝑄𝑄, where E is FabH, A and B are acetyl-CoA and malonyl-CoA, respectively, 
P and Q are products (CoA and acetoactyl-CoA), and E* is the intermediate (acetyl-adduct) state 
of FabH. NaCl is assumed to inhibit the second reaction governed by FabH. 
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FIGURE 1.  Denaturation temperature as a function of salt concentration. The transition 
temperature rises with increasing concentrations of ammonium sulfate (○), NaCl (●), or NaBr 
( ).  Thermal scans used 1.0 mg/mL wt-FabH, 5x Sypro Orange, and 50 mM Hepes buffer, pH 
7.0. 
 
FIGURE 2.  Denaturation temperature as a function of NaCl concentration of wild-type and 
C112S FabH. Thermal scans used 1.0 mg/ml wt-FabH (●), C112S-FabH (▲), 5x Sypro Orange, 
and 50 mM Hepes buffer, pH 7.0. 
The model was modified to add NaCl inhibition, 𝐸𝐸∗ + 𝐼𝐼 →  𝐸𝐸∗𝐼𝐼 where I is the NaCl as an 
inhibitor. Enzyme concentration and substrate concentrations were fixed, whereas equilibrium 
constants were treated as adjustable parameters using DynaFit. Experimental and calculated data 
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are plotted in Fig. 4. Increasing NaCl concentrations inhibits the production of CoA with a Ki 
value of 71 mM for wild-type FabH. 
 
FIGURE 3. Confirming FabH enzyme activity using double-reciprocal plots. Plots represent rate 
of CoA production at varying total concentration of acetyl-CoA added to 1 µM wild-type FabH, 
50 µM malonyl-CoA, 20 µM 7-diethylamino-3-(4'-maleimidylphenyl)-4-methylcoumarin (CPM), 
and 50 mM Hepes, pH 7.0. 
TABLE 1. Values for kinetic parameters for wild-type FabH. Km , apparent Vmax, specific 
activity (SA) and kcat come from initial velocity kinetics, whereas Ki for inhibition due to NaCl 
comes from approach-to-equilibrium data. 
Km (mM) 
Apparent 
Vmax (µM/s) SA (µmol/min/mg) kcat (s-1) Ki (mM) 
0.04 (3) 0.001 (1) 4 (5) 2 (3) 70 (60) 
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FIGURE 4. Effect of NaCl on enzyme activity. Plots represent production of CoA at varying 
total concentration of NaCl: 0 (○), 25 (△), and 100 mM (□) added to 2 μM wt-FabH, 50 µM 
malonyl-CoA, 100 µM Acetyl-CoA, 20 µM 7-diethylamino-3-(4'-maleimidylphenyl)-4-
methylcoumarin (CPM), and 50 mM Hepes buffer, pH 7.0. Each solid line was calculated using 
a theoretical model fitted to data points by DynaFit. 
Crystallization and data collection of FabH— Crystals grew within two days from 
droplets that combined protein, well and ligand solutions in a volume ratio of 1:1:1. Droplets had 
a volume of 3 μL. Details regarding the FabH constructs and conditions of crystallization appear 
as footnotes to column headers of Table 2. The key finding was the presence of the acetyl adduct 
in wild-type FabH and C112S FabH without the addition of acetyl-CoA.  n other words, the 
protein isolated from E.coli came with the acetyl adduct in place, and this adduct resisted 
hydrolysis throughout protein isolation and crystallization. 
Analysis of crystal structures— A bromine ion (Fig. 5) appears consistently in crystals 
which came from crystallization conditions that included NaBr (columns 3—5 of Table 2). This 
binding site is not located at the FabH active site, but instead close to the dimer interface. The 
presence of a single, well-defined site for bromide is consistent with thermal denaturation (Fig. 
1). Surrounding functional groups from the protein are proton donors in hydrogen bonds with 
donor-acceptor distances from 3 to 4 Å.  The thermal parameter (B) for bromide is 28 Å2 
(assuming full occupancy), whereas thermal parameters for atoms of neighboring side chains  
average to 19 Å2.  The refinement of Cl– at this site (again assuming full occupancy) results in a 
B-value of 14 Å2.   
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TABLE 2. Data collection and refinement statistics. 
 
Footnotes to Table 2. 
Column 1: Protein solution, 10–20 mg/mL wild-type FabH in 20 mM Hepes pH 7.0 and 100 mM 
NaCl.  Well solution, 50 mM MgCl, 0.1 M Tris Base pH 8.5, and 29% PEG 4000.  Ligand 
solution,10 mM acetyl CoA in 20 mM Hepes pH 7.0. 
Column 2: Protein solution, 10 mg/mL wild-type FabH and 20 mg/mL holo-ACP in 20 mM 
Hepes pH 7.0 and 100 mM NaCl.  Well solution, 0.2 M calcium acetate, 0.1 M sodium 
cacodylate pH 6.5, and 22% PEG 8000.  Ligand solution, 10 mM acetyl CoA in 20 mM Hepes 
pH 7.0. 
Column 3: Protein solution, 10–20 mg/mL selenomethionine (SeMet) wild-type FabH in 20 mM 
Hepes pH 7.0 and 100 mM NaCl.  Well solution, 0.3 M NaBr, 0.1 M Hepes pH 7.0, and 25% 
PEG 8000. Ligand solution, water. 
Column 4: Protein solution, 10–20 mg/mL C112S FabH in 20 mM Hepes pH 7.0 and 100 mM 
NaCl. Well solution, 0.2 M NaBr, 0.1 M Hepes pH 7.0, and 27% PEG 8000.  Ligand solution, 
water.  The crystal was removed from its protein droplet and soaked in a droplet of 20 mM 
Hepes pH 7.0 solution for several hours before flash-freezing. 
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Column 5: Protein solution, 10–20 mg/mL C112S FabH in 20 mM Hepes pH 7.0 and 100 mM 
NaCl.  Well solution, 0.3 M NaBr, 0.1 M Sodium cacodylate pH 7.0, and 26% PEG 6000.  
Ligand solution, water. 
 
 
FIGURE 5.  The binding of bromide to FabH. (A) Ribbon drawing showing the bromide site 
relative to the dimer interface. Bromide is indicate by the magenta sphere.  (B) Electron density 
and protein side chains near the bound bromide.  The box in Panel A is the region of viewing in 
Panel B. 
Electron density here becomes much weaker in structures that come from crystallization 
conditions that exclude NaBr, suggesting that the observed density is largely due to bound Br–. 
Electron density for chloride appears juxtaposed to the carbonyl carbon of the acetyl 
adduct of Cys112 or Ser112 (structures represented by columns 3 and 5 of Fig. 6; Table 2).  Cl– 
(at full occupancy) refines at these positions with B-values of 14 Å2, which is comparable to B-
values of the acetyl adduct.  The B-values for water molecules refined in the same density were 
below 5 Å2.  Regardless of the mutation at position 112, the acetyl adduct appears associated 
with strong electron density, and refines with atomic B-values comparable to those of 
neighboring residues of the protein.  In addition, the carbonyl group of the acetyl adduct 
hydrogen bonds with backbone amides of Gly306 and Cys112 (or Ser112), presumably 
localizing negative charge on the oxygen atom, and thereby generating positive charge on the 
carbon atom of the carbonyl.  That positive charge in turn is stabilized by the juxtaposed chloride 
ion. 
Br- 
Gln93 
Ser52 
Thr84 
Thr50 B A 
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FIGURE 6.  Halide, acetyl adduct, and the CoA-bound active site. (A) Wild-type FabH with 
adduct and Cl–.  (B) C112S-FabH with adduct and Cl–.  (C) Mixed acetyl-CoA/CoA-adduct 
complex showing the CoA moiety in an extended conformation.  (D) Electron density reflecting 
a mixed state of CoA disulfide-linked to Cys112 and adduct-lined to Cys112. 
Exposure of crystals to a solution without NaCl results in the loss of the adduct (structure 
represented by column 4 of Table 2). Electron density in proximity to the site assigned to Cl– is 
diminished and can be explained by a water molecule, the B-values for which match those of the 
surrounding protein atoms. 
CoA appears to form a disulfide link Cys112 (Fig. 6). Electron density in the active site 
indicates a mixed state, with fractional occupancy by the acetyl adduct and CoA, with CoA 
dominant.  CoA is in strong electron density (Figs. 6C & 6D) and the distal amide group of the 
pantothenate moiety hydrogen bonds with Asn247 and Gly209. The same residue pair likely 
recognizes the proximal amide group of the pantothenate moiety of malonyl-ACP (Fig. 7). The 
adenyl and phosphoryl groups of CoA interact with the active site as observed in a CoA complex 
in which the disulfide bond is absent (23). The observation of a disulfide-linked CoA at the 
active site of FabH suggest a purpose in forming the acetyl adduct of Cys112 and stabilizing it 
through a charge interaction with Cl– (see Discussion section). 
A B 
C D 
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FIGURE 7.  Recognition of malonyl-ACP relative to acetyl-CoA. (A) The distal amide linkage 
of acetyl-CoA is recognized by hydrogen bonds involving Gly209 and Asn247.  In order to 
provide sufficient space for the acetyl adduct and the malonyl moiety of malonyl-ACP, we 
suggest recognition of the proximal amide linkage of the pantothenate moiety of malonyl-ACP 
by Gly209 and Asn247 (B). 
The disordered structure of FabH, missing 28 residues from a long loop that covers the 
active site (Fig. 8), has been observed before (23) and is presented here without detailed analysis; 
however, this opened conformation of FabH has no acetyl adduct at Cys112, and no electron 
density for Cl–. 
 
A 
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FIGURE 8.  Disorder in the wild-type FabH. Dimer of wt-FabH (A) showing region of disorder 
(red).  The side chain of Cys112 marks the active site.  Electron density in proximity to Cys112 
in the ordered dimer (B) and locally disordered dimer (C).  Region of viewing indicated by the 
box in Panel A. 
DISCUSSION 
FabH when over-expressed in E. coli, comes through rapid preparations with the acetyl 
adduct in place as revealed by crystal structures. The persistence of this intermediate state (the 
state that occurs after the priming reaction) is unexpected, and suggests that a stabilization 
mechanism protects the acetyl adduct of Cys112 from hydrolysis. Moreover, the result indicate 
sthat the intermediate (acetyl-adduct) state of FabH may be that which dominates in vivo. 
No law of nature requires that an enzyme prefer its ligand free state. An enzyme goes 
through a catalytic cycle. The cycle can begin with the primed (acetyl-adduct) state, undergo 
A 
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reaction with malonyl-ACP, release products, and “finish” with the priming reaction to 
regenerate the acetyl adduct. The “resting” state of the enzyme, then could be as easily the 
primed state as the unmodified (free) state. In fact, there may be an advantages in maintaining an 
acetyl-modified as opposed to an unmodified enzyme in vivo. The thiol group of Cys112 is 
reactive, and evidently can form other kinds of adducts, the formation of which may not be easy 
to reverse. The disulfide bond formed between the sulfur atom of Cys112 and the sulfur atom of 
CoA could be one such adduct. The presence of CoA in the active site designed to fit CoA 
blocks other metabolites from entering the active site. Once formed then, what chemical process 
can reduce a disulfide linkage that is blocked and buried in the core of the enzyme, short of 
unfolding the protein and exposing that link to the solvent? Hence, a mechanism that maintains 
the acetyl-adduct of Cys112 can protect FabH from inadvertent and damaging chemistry. 
Thermal denaturation data here shows that the acetyl adduct of Cys112 is likely to 
enhance thermal stability of FabH. Crystal structures indicate the presence of Cl– in what is 
probably an electrostatic interaction with the partial positive charge of the carbonyl carbon of the 
acetyl adduct. Cl– inhibition of FabH with a Ki of ~70 mM (comparable to physiological levels of 
Cl–) is consistent with crystallographic data. We suggest then, that acetyl adduct is stabilized by 
electrostatic pairing with an anion, and that the most likely anion involved in this process is Cl–. 
As further evidence, exposure of crystals to a solvent free of NaCl, results in the loss of the 
acetyl adduct. 
With respect to the goal of engineering FabH to accept something other than an acetyl 
adduct in the priming reaction, an additional consideration of enzyme stability emerges from this 
study. The goal is to form an adduct complex leaving key active site residues in place and 
retaining the anion stabilization/protection mechanism. The anion preferably should be Cl–, as it 
is plentiful and relatively constant in concentration in vivo. Cl– does not form strong hydrogen 
bonds, and hence is easily displaced by malonyl-ACP. The challenge lies in expanding the 
volume of the active to accommodate an adduct significantly larger than the acetyl group without 
destabilizing the enzyme in its adduct-free state. 
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CHAPTER 6: GENERAL CONCLUSIONS 
TNP-nucleotides and ATP release HKI from the mitochondrion; however, results of 
Chapter 2 eliminate nucleotide binding to HKI as the basis for release. The findings of Chapter 2 
are negative, determining mechanisms that are not responsible for ATP-release of HKI, and 
attributing the phenomenon to ATP binding to VDAC. 
Suspecting a role for VDAC is easy; proving that ATP binds to hVDAC-1 and releases 
HKI is difficult. In fact, the evidence for a high-affinity binding site on VDAC for ATP is weak. 
Analogs of ATP may bind tightly, but no specific residue of VDAC is linked unequivocally to an 
ATP binding site. Work of Chapter 3 identifies Lys256 as a major determinant in ATP and TNP-
AMP binding to VDAC. Moreover, the incorporation of tryptophan at two positions 7 and 18 of 
the N-terminal helix of VDAC indicates tighter association of that helix with the core of VDAC 
in the presence of TNP-ATP, than in its absence. These observations suggest a stable complex of 
ATP and TNP-nucleotides with VDAC. 
How then does VDAC pass ATP from the intermembrane space of the mitochondrion to 
the cytosol if it forms a complex of high stability with ATP? Some have suggested VDAC 
localizes to tight junctions between outer and inner membranes of the mitochondrion. 
Components of tight junctions include the adenylate translocator of the inner membrane, VDAC 
of the outer membrane and a HKI at the outer membrane surface. These proteins co-purify from 
detergent-solubilized mitochondria, but whether the 500 kDa complex is relevant to the 
organization of proteins at the tight junction is unknown. Nonetheless, VDAC alone may be an 
incomplete system, and that interactions with the adenylate translocator and/or HKI may 
regulate/facilitate the function of VDAC. On the other hand, VDAC could function 
independently of other proteins, and as suggested in Chapter 3, could have two binding sites for 
ATP. The site of high-affinity could bind and stabilize a closed pore. As ATP concentrations 
build in the intermembrane space of the mitochondrion, a second molecule of ATP binds to 
VDAC at the low affinity site. The pore opens in response to the second binding event, and in so 
doing destabilizes the tight binding site for ATP, allowing the nucleotide to pass on to the 
cytosol. Hence, ATP plugs the pore of VDAC, waiting for the mitochondrion to generate an ATP 
gradient that thermodynamically pushes ATP into the cytosol. 
Evidence of ATP binding to VDAC leading to the release of HKI comes in Chapter 4. 
Here a vesicle system of embedded VDAC and surface-bound N-terminal half HKI qualitatively 
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reproduces the interaction of HKI with the outer membrane of the mitochondrion. The N-
terminal half of HKI releases from VDAC-embedded vesicles in response to glucose 6-
phosphate and ATP as does HKI from the mitochondrion. The N-terminal “tail” of HKI also 
binds to VDAC-embedded vesicles (but not to vesicles without VDAC). The N-terminal tail does 
not release in response to glucose 6-phosphate, which is an expected outcome as the glucose 6-
phosphate binding site is not included in the tail construct. Release of the tail by ATP, however, 
is less effective than for the N-terminal half, suggesting structural elements of the N-terminal 
half besides the tail are involved in the recognition of VDAC. 
It is not unreasonable to suggest the next experiment to be done in the investigation of 
interactions between VDAC and HKI. Clearly, the incorporation of any of the VDAC mutant 
proteins into vesicles is feasible. The 15 lysine mutants of VDAC exhibit wild-type CD spectra, 
indicating wild-type protein folds. Incorporation of K256M VDAC would test whether the high-
affinity binding site for ATP is responsible for the release of the N-terminal half of HKI. 
Moreover, using the model for the complex of VDAC and N-terminal half HKI (Maskey, MS 
thesis) specific mutations of N-terminal half HKI can identify other structural determinates of 
HKI involved in VDAC recognition. 
The second part of the thesis focuses on factors that stabilize FabH. Not surprisingly, 
additives frequently used in the crystallization of proteins enhanced the stability of FabH; 
however, the mechanism of stabilization varied. Br– binds to a single site, readily observed in 
crystal structures of FabH. The protective effects of Br– seem limited to a single site as the 
temperature of thermal denaturation plateaus at concentrations of Br– above 150 mM. Bromide 
stabilization of FabH is fortuitous, and likely not physiologically significant. 
The mechanism of chloride stabilization seems more complex, involving multiple 
binding sites. At concentrations of approximately 100 mM Cl–, however, a single chloride anion 
appears juxtaposed to the acetyl adduct of Cys112, suggesting an electrostatic charge interaction 
between the anion and partial positive charge of the carbonyl carbon of the acetyl adduct. The 
presence of chloride here may account for the isolation of the Cys112-adduct form of FabH from 
E. coli, and suggests the predominant state of the enzyme in vivo as the adduct intermediate. The 
presence of chloride protects the acetyl adduct of Cys112 from hydrolysis, and the adduct form 
of the enzyme protects the thiol of Cys112 from oxidation. The occurrence of a disulfide linked 
molecule of CoA to the sulfur atom of Cys112 is an example of a dead-end reaction that could 
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happen in vivo.  Hence, we hypothesize that the role of chloride in conjunction with the acetyl 
adduct is physiological, protecting FabH from rogue chemical reactions involving Cys112. We 
suggest then, that in engineering FabH to accept different substrates in the priming reaction, that 
the protective mechanism of chloride be retained. 
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